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A B S T R A C T
Background
Peripheral arterial disease (PAD), caused by narrowing of the arteries in the limbs, is increasing in incidence and prevalence as our
population is ageing and as diabetes is becoming more prevalent. PAD can cause pain in the limbs while walking, known as intermittent
claudication, or can be more severe and cause pain while at rest, ulceration, and ultimately gangrene and limb loss. This more severe
stage of PAD is known as ’critical limb ischaemia’. Treatments for PAD include medications that help to reduce the increased risk of
cardiovascular events and help improve blood flow, as well as endovascular or surgical repair or bypass of the blocked arteries. However,
many people are unresponsive to medications and are not suited to surgical or endovascular treatment, leaving amputation as the last
option. Gene therapy is a novel approach in which genetic material encoding for proteins that may help increase revascularisation is
injected into the affected limbs of patients. This type of treatment has been shown to be safe, but its efficacy, especially regarding ulcer
healing, effects on quality of life, and other symptomatic outcomes remain unknown.
Objectives
To assess the effects of gene therapy for symptomatic peripheral arterial disease.
Search methods
The Cochrane Vascular Information Specialist searched Cochrane CENTRAL, the Cochrane Vascular Specialised Register, MEDLINE
Ovid, Embase Ovid, CINAHL, and AMED, along with trials registries (all searched 27 November 2017). We also checked reference
lists of included studies and systematic reviews for further studies.
Selection criteria
We included randomised and quasi-randomised studies that evaluated gene therapy versus no gene therapy in people with PAD. We
excluded studies that evaluated direct growth hormone treatment or cell-based treatments.
Data collection and analysis
Two review authors independently selected studies, performed quality assessment, and extracted data from the included studies. We
collected pertinent information on each study, as well as data for the outcomes of amputation-free survival, ulcer healing, quality of
life, amputation, all-cause mortality, ankle brachial index, symptom scores, and claudication distance.
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Main results
We included in this review a total of 17 studies with 1988 participants (evidence current until November 2017). Three studies
limited their inclusion to people with intermittent claudication, 12 limited inclusion to people with varying levels of critical limb
ischaemia, and two included people with either condition. Study investigators evaluated many different types of gene therapies, using
different protocols. Most studies evaluated growth factor-encoding gene therapy, with six studies using vascular endothelial growth
factor (VEGF)-encoding genes, four using hepatocyte growth factor (HGF)-encoding genes, and three using fibroblast growth factor
(FGF)-encoded genes. Two studies evaluated hypoxia-inducible factor 1-alpha (HIF-1α) gene therapy, one study used a developmental
endothelial locus-1 gene therapy, and the final study evaluated a stromal cell-derived factor-1 (SDF-1) gene therapy. Most studies
reported outcomes after 12 months of follow-up, but follow-up ranged from three months to two years.
Overall risk of bias varied between studies, with many studies not providing sufficient detail for adequate determination of low risk
of bias for many domains. Two studies did not utilise a placebo control, leading to risk of performance bias. Several studies reported
in previous protocols or in their Methods sections that they would report on certain outcomes for which no data were then reported,
increasing risk of reporting bias. All included studies reported sponsorships from corporate entities that led to unclear risk of other bias.
The overall quality of evidence ranged from moderate to very low, generally as the result of heterogeneity and imprecision, with few or
no studies reporting on outcomes.
Evidence suggests no clear differences for the outcomes of amputation-free survival, major amputation, and all-cause mortality between
those treated with gene therapy and those not receiving this treatment (all moderate-quality evidence). Low-quality evidence suggests
improvement in complete ulcer healing with gene therapy (odds ratio (OR) 2.16, 95% confidence interval (CI) 1.02 to 4.59; P =
0.04). We could not combine data on quality of life and can draw no conclusions at this time regarding this outcome (very low-quality
evidence). We included one study in the meta-analysis for ankle brachial index, which showed no clear differences between treatments,
but we can draw no overall association (low-quality evidence). We combined in a meta-analysis pain symptom scores as assessed by visual
analogue scales from two studies and found no clear differences between treatment groups (very low-quality evidence). We carried out
extensive subgroup analyses by PAD classification, dosage schedule, vector type, and gene used but identified no substantial differences.
Authors’ conclusions
Moderate-quality evidence shows no clear differences in amputation-free survival, major amputation, and all-cause mortality between
those treated with gene therapy and those not receiving gene therapy. Some evidence suggests that gene therapy may lead to improved
complete ulcer healing, but this outcome needs to be explored with improved reporting of the measure, such as decreased ulcer area
in cm², and better description of ulcer types and healing. Further standardised data that are amenable to meta-analysis are needed to
evaluate other outcomes such as quality of life, ankle brachial index, symptom scores, and claudication distance.
P L A I N L A N G U A G E S U M M A R Y
Gene therapy for peripheral arterial disease
Background
Peripheral arterial disease (PAD) occurs when the blood flow to the limbs is restricted because of narrowed arteries. This circulatory
problem is increasing in the population because of increased levels of diabetes and because the population is ageing. Due to restricted
blood flow, PAD can cause pain in the legs while walking, usually after some distance (known as ’intermittent claudication’). As the
disease becomes more severe, a person can experience serious pain while at rest, as well as ulcers in the feet and legs (known as ’critical
limb ischaemia’). PAD can be treated with medication or through interventions such as surgical or endovascular procedures (less invasive
than surgery, endovascular intervention is carried out through a small incision to access the vessels). However, many people will not
respond to medication, and surgical or endovascular procedures may not be appropriate because of medical risks. In these cases, for
extreme PAD, the only option for treating the condition is amputation. Therapies are needed that can help repair the vessels in the
limbs of people with PAD to restore adequate blood flow.
Gene therapy is a novel approach whereby genetic material, encoded for proteins that may help to improve blood flow by restoring
blood vessels, is injected into a person’s legs. Trials have shown that this treatment is safe, but whether it is effective in reducing the risk
of amputation or improving quality of life remains unknown.
Review question
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Is there a difference in outcomes of effectiveness (such as amputation, death, ulcer healing, and quality of life) between patients with
symptomatic PAD who are given gene therapy and those who are not given gene therapy?
Study characteristics
We included 17 studies that had a total of 1988 participants (evidence current until November 2017). These studies used various
types of gene therapy as well as different dosages, some providing single treatments and some repeated treatments. Most of the studies
included people with critical limb ischaemia; three studies included people with intermittent claudication.
Key results
When combining the data, we found no clear differences between people who received gene therapy and those who did not in terms
of amputation-free survival (patients who did not have an amputation and did not die), major amputation (above the ankle), or death.
We did see improvement in complete ulcer healing in the gene therapy treatment group compared to the control group. Studies show
no clear differences in pain symptom scores, but we evaluated only two studies for this outcome. Not enough data are available to
show if there was a difference between groups for the measure of blood flow known as the ’ankle brachial index’. We were not able to
combine data on quality of life or pain-free walking distances (distances one can walk without experiencing leg pain).
Quality of the evidence
Risk of bias of the included studies varied greatly, and this was a concern because studies did not clearly report on their methods nor
on follow-up of participants. Most studies used a placebo control, which increases the risk that outcomes may have been different if
people knew they were given treatment or control. Corporations that produce the tested treatments sponsored all included trials.
The quality of evidence varied from moderate to very low. For amputation-free survival, major amputation, and death, we considered
the quality of evidence to be moderate because of differences between studies. For ulcer healing, risk of bias was a matter of concern,
and study results were imprecise because few events were reported. The quality of evidence for quality of life was very low because of
differences between studies and insufficient information to combine study findings. The quality of evidence for the ankle brachial index
was low because only one study with few participants reported this outcome. For pain symptom scores, the quality of evidence was very
low because of technical problems within one of the two studies, as well as differences between the two studies and few participants.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Gene therapy compared to no gene therapy control for peripheral arterial disease
Patient or population: peripheral arterial disease
Setting: inpat ient treatment with outpat ient follow-up
Intervention: gene therapy
Comparison: no gene therapy control
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GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aEvidence of substant ial heterogeneity between studies (73%).
bRisk of bias in most included studies due to study design or protocol execut ion.
cImprecision in ef fect est imate due to few events, leading to wide conf idence interval.
dSubstant ial heterogeneity between how studies reported on the outcome, making meta-analysis inappropriate.
eCannot est imate ef fect due to insuf f icient information provided by studies.
f Lit t le overall heterogeneity detected, but the largest included study reported a very dif f erent rate of events compared with
the other studies.
gOnly one study in the meta-analysis, with few part icipants, leading to imprecision.
hRisk of bias; one of the two included studies incurred technical problems that study authors reported led to unreliable and
uninterpretable data.
iEvidence of moderate heterogeneity (46%).























































































B A C K G R O U N D
Description of the condition
The global burden of peripheral arterial disease (PAD) is increasing
because of the rising prevalence of diabetes mellitus and an ageing
population (Fowkes 2013). However, not all individual countries
are experiencing an increase in PAD, as was evidenced in a re-
cent study in the UK (Cea-Soriano 2018). Whilst PAD can be
asymptomatic, it may also present with either intermittent clau-
dication (IC) of varying severity or one or more manifestations
of critical limb ischaemia (CLI), including rest pain, ischaemic
ulcers, and gangrene (Norgren 2007). Treatment goals for claudi-
cants versus patients with critical limb ischaemia are different, pre-
dominantly due to disease severity and concomitant comorbidity.
Conventional management involves medical therapy for risk fac-
tor modification, pain relief, and treatment of infection, as well as
interventions to relieve vascular obstruction through surgical pro-
cedures, endovascular approaches, or both (Mohler 2008). How-
ever, many cases are not amenable to these interventions because
of patients’ existing comorbidities and the complexity of their vas-
cular anatomy due to multiple, diffuse, and distal disease. In CLI,
this may result in amputation of the ischaemic limb. Hence, novel
therapy is urgently needed to combat this unmet clinical need,
and therapeutic revascularisation with gene therapy represents a
promising new approach for the management of PAD.
Description of the intervention
Therapeutic revascularisation for management of PAD is possi-
ble via gene therapy. Recent randomised controlled trials (RCTs)
utilising gene therapy for patients with PAD have involved the
transfer of genetic material (DNA or RNA) into cells to modify
their genetic expression. Gene therapy can be administered on one
or more occasions via intra-arterial or intramuscular routes. It can
target a specific gene or multiple genes to either augment or atten-
uate specific gene expression, leading to therapeutic revascularisa-
tion.
A previous meta-analysis has shown that gene therapy is safe and
feasible, with some evidence of clinical improvement in patients
with PAD (De Haro 2009), but it should be noted that systemic
safety analysis has not been fully evaluated at this time. Gene
therapy is a limb-specific therapy that may not decrease mortality
or risk of cardiac events.
How the intervention might work
Gene therapy can be performed by direct delivery of specific ge-
netic materials (DNA or RNA) into cells via several viral- or non-
viral-based methods (Kealy 2009; Liew 2013; Scougall 2003). This
process can result in significant changes in specific gene expression
leading to therapeutic revascularisation through stimulation of an-
giogenesis. Gene expression occurs when a cell’s gene(s) are used to
make a substance that changes the way the cell functions. In some
cases, this change may improve or prevent a medical condition.
The induction of therapeutic revascularisation can potentially lead
to relief of symptoms associated with claudication in patients with
PAD through formation of new blood vessels at ischaemic sites.
It may also mobilise distant regenerative stem cell populations to
ischaemic sites, thereby restoring the structure and function of
surrounding ischaemic tissues (Asahara 1997; Kuliszewski 2011).
Hence, improvement in blood flow in the affected limb(s) may
potentially negate the need for amputation in critical ischaemia.
Why it is important to do this review
A previous meta-analysis showed that gene therapy is safe and fea-
sible, with some evidence of clinical improvement in patients with
PAD (De Haro 2009). Since then, researchers have completed nu-
merous RCTs using gene therapy to treat patients with PAD. How-
ever, these RCTs have reported inconsistent overall efficacy out-
comes (Anghel 2011; Belch 2011; Creager 2011; Grossman 2007;
Kusumanto 2006; Makinen 2002; Nikol 2008; Powell 2008;
Powell 2010; Rajagopalan 2003; Rajagopalan 2007; Shigematsu
2010). Meta-analysis showed that gene therapy neither signifi-
cantly increased nor decreased all-cause mortality, amputation, or
ulcer healing in patients with PAD (Hammer 2013). Furthermore,
its effect on patients’ quality of life is currently unclear.
In 2009, the Society for Vascular Surgery (SVS) published guide-
lines to improve the consistency and interpretability of all clinical
trials conducted to evaluate potential treatment options for pa-
tients with CLI and suggested the following endpoints.
1. MALE (major adverse limb event: above-ankle amputation
of the index limb or major reintervention (new bypass graft,
jump/interposition graft revision, or thrombectomy/
thrombolysis)).
2. MALE or POD (perioperative death (30 days), or any
MALE).
3. MACE (major adverse cardiovascular event: myocardial
infarction (MI), stroke, or death (any cause)).
4. Amputation (above-ankle amputation of the index limb).
5. AFS (amputation-free survival: above-ankle amputation of
the index limb or death (any cause)).
6. RAO (any reintervention or above-ankle amputation of the
index limb).
7. RAS (any reintervention, above-ankle amputation of the
index limb, or stenosis and all-cause mortality).
Researchers presented these endpoints with suggested correspond-
ing objective performance goals (OPGs) and designed them to
meet US Federal Drug Administration (FDA) regulations by pro-
viding a framework for determining the appropriate entry of a
novel therapy onto the market (Conte 2009).
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Hence, the principal objective of this review is to provide the best
estimate for the effects of gene therapy on two of these endpoints
(amputation and amputation-free survival) and on quality of life,
as well as other commonly reported efficacy and safety outcome
measures. This review will provide a better understanding of the
efficacy of gene therapy in PAD, thereby helping to guide the
future direction of gene therapy for this patient cohort.
O B J E C T I V E S
To assess the effects of gene therapy for symptomatic peripheral
arterial disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) and quasi-
RCTs that compared gene therapy versus no gene therapy as treat-
ment for patients with symptomatic PAD. We considered for in-
clusion cross-over trials, cluster-randomised trials, and multiple
observations for the same outcome.
Types of participants
Our review included all patients (men and women with no age
restriction) who had received a diagnosis of symptomatic PAD
(intermittent claudication and critical limb ischaemia) of the lower
extremities by an expert clinician after clinical and investigative
assessment (by ankle brachial pressure index (ABI), exercise testing,
duplex scanning, or angiography).
Types of interventions
We included only RCTs that compared gene therapy versus no
gene therapy for patients with symptomatic PAD. We included all
types of gene therapy, regardless of dosage or administration fre-
quency or route of administration (systemic or local). We consid-
ered trials involving direct growth factor delivery (treatment with
direct growth factor protein as opposed to a viral or plasmid vector
containing genes encoding for a growth factor) or cell therapy to
be not relevant. The minimum period of follow-up allowed was
three months.
Types of outcome measures
Primary outcomes
1. Amputation-free survival (above-ankle amputation of the
index limb or death (any cause))
2. Ulcer healing
3. Quality of life (as assessed by formal questionnaires)
Secondary outcomes
1. Amputation (above-ankle amputation of the index limb)
2. All-cause mortality
3. Ankle brachial index (ABI)
4. Symptom scores (e.g. pain scores)
5. Claudication distance
Search methods for identification of studies
We applied no language, publication year or publication status
restrictions.
Electronic searches
The Cochrane Vascular Information Specialist conducted system-
atic searches of the following databases.
1. The Cochrane Vascular Specialised Register via the
Cochrane Register of Studies (CRS-Web searched from
inception to 27 November 2017).
2. The Cochrane Central Register of Controlled Trials
(CENTRAL) Cochrane Register of Studies Online (CRSO
2017, Issue 10).
3. MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MEDLINE®
Daily and Ovid MEDLINE®) (searched from 1 January 2017 to
27 November 2017).
4. Embase Ovid (searched from 1 January 2017 to 27
November 2017).
5. CINAHL Ebsco (searched from 1 January 2017 to 27
November 2017).
6. AMED Ovid (searched from 1 January 2017 to 27
November 2017).
The Information Specialist modelled search strategies for other
databases on the search strategy designed for CENTRAL. Where
appropriate, they were combined with adaptations of the highly
sensitive search strategy designed by the Cochrane Collaboration
for identifying randomised controlled trials and controlled clinical
trials (as described in the Cochrane Handbook for Systematic Reviews
of Interventions Chapter 6, Lefebvre 2011). Search strategies for
major databases are provided in Appendix 1.
The Cochrane Vascular Information Specialist also searched the
following trials registries on 27 November 2017.
8Gene therapy for peripheral arterial disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. World Health Organization International Clinical Trials
Registry Platform (who.int/trialsearch).
2. ClinicalTrials.gov ( clinicaltrials.gov)
Searching other resources
We handsearched references within identified RCTs and meta-
analyses for additional relevant studies.
Data collection and analysis
Selection of studies
Two review authors (AL and RF) independently selected RCTs
for inclusion in the review, resolving discrepancies through joint
discussion with the other review authors (VB, JS, and GS). Two
review authors (AL and RF) independently reviewed the abstracts,
titles, or both, of every record retrieved, to determine which studies
needed further assessment. When we identified relevant articles,
we obtained the full texts of these articles, and two review authors
(AL and RF) independently applied review inclusion criteria.
Data extraction and management
Two review authors (AL and RF) independently examined all in-
cluded RCTs and extracted all relevant data. We resolved disagree-
ments by consensus with the other review authors (VB, JS, and
GS). For primary RCTs with duplicate or multiple publications
(e.g. interim analyses), we collated all available data and used the
most complete data set aggregated across all known publications.
Assessment of risk of bias in included studies
Two review authors (AL and RF) independently assessed poten-
tial risks of bias for all included RCTs using the Cochrane tool
for assessing risk of bias (Higgins 2011). This tool assesses bias
in six different domains: sequence generation; allocation conceal-
ment; blinding of participants, personnel, and outcome assessors;
incomplete outcome data; selective outcome reporting; and other
sources of bias. Each domain received a score of high, low, or un-
clear depending on each review author’s judgement. The other re-
view authors (VB, JS, and GS) were available to act as adjudicators
in the event of disagreement.
We searched for protocols of included RCTs and compared out-
comes in the protocol against those in the published report. If the
protocol was not available, we compared outcomes listed in the
Methods section of the RCT report versus actual reported results
(Higgins 2011).
Measures of treatment effect
For dichotomous outcomes, we expressed results as odds ratios
(ORs) with 95% confidence intervals (CIs). For continuous scales
of measurement, we expressed results as mean differences (MDs).
Furthermore, we planned to use standardised mean differences
(SMDs) if RCTs used different scales. We planned to present time-
to-event data as hazard ratios (HRs) with 95% CIs.
Unit of analysis issues
The unit of analysis within each trial was the individual partici-
pant. If necessary, two review authors (AL and RF) planned to con-
sider the level at which randomisation occurred, such as in cross-
over and cluster-randomised trials, and multiple observations for
the same outcome. Again, we planned to resolve discrepancies
through joint discussion with the other review authors (VB, JS,
and GS).
Dealing with missing data
When necessary, we planned to request required further informa-
tion from the original trial authors via written correspondence (e.g.
emails to corresponding author(s)), and we planned to include in
the review all relevant information obtained in this manner. We
critically appraised issues related to missing data and imputation
methods (e.g. last observation carried forward) and investigated
attrition rates, including dropouts, losses to follow-up, and with-
drawals (Higgins 2011). For meta-analysis, we included all partic-
ipants randomised in each trial, when appropriate, to reduce the
effects of attrition bias.
Assessment of heterogeneity
Clinical heterogeneity
Before performing data analysis, we assessed all included RCTs for
potential clinical heterogeneity. We planned to conduct a subgroup
analysis for any clinical outliers. However, we performed a meta-
analysis initially regardless of the presence of clinical heterogeneity.
Methodological heterogeneity
Before analysing data, we assessed all included RCTs for poten-
tial methodological heterogeneity. We planned to perform several
subgroup analyses to detect methodological outliers. However, we
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We assessed the possibility of statistical heterogeneity through di-
rect visual inspection of the graphs.
I² statistic
We assessed heterogeneity between studies using the I² statistic
with the associated Chi² test (Higgins 2003). We interpreted an
I² estimate of 50% or above with a corresponding statistically sig-
nificant Chi² test as evidence of substantial levels of heterogeneity.
We performed subgroup analyses to explore reasons for the het-
erogeneity (Higgins 2011).
Assessment of reporting biases
We planned to use funnel plots to assess publication bias unless
we identified 10 or fewer RCTs, or all RCTs were of similar size,
because these circumstances would have limited power for detect-
ing a small-study effect (Higgins 2011).
Data synthesis
We used a fixed-effect model to calculate pooled treatment of ef-
fect data and presented the estimates as ORs or MDs with their re-
spective 95% CIs for binary and continuous outcome variables, as
detailed above. We used the random-effects model if we observed
significant heterogeneity (defined as I² > 50%). We planned to
report the absolute risk reduction/increase as a weighted estimate
of the difference in event rates. We considered a two-sided P value
less than 0.05 to be the cutoff point for statistical significance. We
created a forest plot for each outcome, as per Cochrane Vascular
guidelines.
Subgroup analysis and investigation of heterogeneity
In the event of substantial clinical, methodological, or statistical
heterogeneity, we attempted to determine possible reasons by ex-
amining individual study and subgroup characteristics. Neverthe-
less, we planned to perform the following subgroup analyses, re-
gardless of the presence of any heterogeneity.
1. Intermittent claudication versus critical limb ischaemia.
2. Multiple-gene therapy versus single-gene therapy.
3. Repeated gene therapy versus single gene therapy.
4. Routes of administration: intramuscular versus intra-
arterial.
5. Vector type: virus versus plasmid.
6. Presence or absence of diabetes mellitus.
Sensitivity analysis
We planned to perform sensitivity analyses following the exclusion
of:
1. any substantially long or large RCTs, to establish how much
their findings dominated the results;
2. cross-over trials, cluster-randomised trials, and multiple
observations for the same outcome; and
3. any RCTs that we judged to be at high risk of bias across
one or more domains of randomisation, allocation concealment,
blinding, and outcome reporting for meta-analysis of the
primary outcome.
We planned to perform sensitivity analyses only if the outcome
had at least three studies remaining after sensitivity analysis.
During study inclusion, we chose to include four studies that did
not meet our robust inclusion criteria for diagnosis of PAD but
did include various measures and descriptors of vascular disease
that we deemed appropriate for inclusion, as investigators most
likely were evaluating the same population as studies that fully
met review criteria (Deev 2015; Kibbe 2014; Powell 2008; Powell
2010). We performed sensitivity analysis by excluding these studies
from their respective meta-analyses to make sure they did not have
an overt effect on review results.
’Summary of findings’ table
We have summarised the results of analyses on primary and sec-
ondary outcomes in a ’Summary of findings’ table, which contains
information regarding the quality of evidence for all relevant out-
comes. We assessed the quality of the body of evidence by consid-
ering the overall risk of bias of included studies, directness of the
evidence, inconsistency of the results, precision of the estimates,
and risk of publication bias according to GRADE (Balshem 2011).
We included in the ’Summary of findings’ table seven outcomes
(amputation-free survival, ulcer healing, quality of life, amputa-
tion, all-cause mortality, ABI, and symptom scores) that we con-
sidered essential for decision-making.
R E S U L T S
Description of studies
Results of the search
We retrieved a total of 3225 references, after de-duplication,
through comprehensive literature searches. After title and abstract
review, we identified 117 references for full-text assessment. Of
these 117, we excluded 16 studies (18 records) with reasons, iden-
tified 11 as duplicate references, considered 40 to be not relevant,
and identified four as ongoing studies. We included a total of 44
records from 17 studies (including one reference for two studies
(Henry 2006 and Nikol 2008)). See Figure 1 for the search results
flow diagram.
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Figure 1. Study flow diagram.
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Included studies
We included in this review a total of 17 randomised trials,
with 1988 randomised participants (Belch 2011; Creager 2011;
Deev 2015; Deev 2017; Grossman 2007; Henry 2006; Kibbe
2014; Kibbe 2016; Kusumanto 2006; Makinen 2002; Mohler
2003; Nikol 2008; Powell 2008; Powell 2010; Rajagopalan 2003;
Rajagopalan 2007; Shigematsu 2010). For detailed descriptions
of these studies, please see Characteristics of included studies.
The types of gene therapy used varied between studies. A total
of six studies evaluated various treatments encoding for vascu-
lar endothelial growth factor (VEGF) (Deev 2015; Deev 2017;
Kusumanto 2006; Makinen 2002; Mohler 2003; Rajagopalan
2003). Four studies evaluated treatments that encoded for hep-
atocyte growth factor (HGF) (Kibbe 2016; Powell 2008; Powell
2010; Shigematsu 2010). Three studies utilised treatments encod-
ing for fibroblast growth factor (FGF), all specifically using non-
viral 1 FGF (NV1FGF) (Belch 2011; Henry 2006; Nikol 2008).
Two studies utilised a hypoxia-inducible factor 1-alpha (HIF-1α)-
encoding treatment (Creager 2011; Rajagopalan 2007). One study
evaluated a treatment encoding for the developmental endothelial
locus-1 (Del-1) protein (Grossman 2007), and one study used a
treatment that encoded for stromal cell-derived factor-1 (SDF-1)
(Kibbe 2014).
Three of the included trials evaluated participants with IC only
(Creager 2011; Grossman 2007; Rajagopalan 2003), and 12 stud-
ies evaluated participants with varying levels of CLI (Belch 2011;
Deev 2017; Henry 2006; Kibbe 2014; Kibbe 2016; Kusumanto
2006; Makinen 2002; Nikol 2008; Powell 2008; Powell 2010;
Rajagopalan 2007; Shigematsu 2010). Two studies evaluated par-
ticipants with IC or CLI (Deev 2015; Mohler 2003).
Most included studies reported their primary analyses after 12
months (Belch 2011; Creager 2011; Kibbe 2014; Kibbe 2016;
Mohler 2003; Nikol 2008; Powell 2008; Rajagopalan 2007). Four
studies reported primary analysis after six months (Deev 2017;
Grossman 2007; Powell 2010; Rajagopalan 2003), and two studies
reported outcomes at or around three months (Kusumanto 2006;
Makinen 2002). One study evaluated outcomes at 15 months
(Deev 2015), and one at two years (Shigematsu 2010). The final
study did not specify follow-up time (Henry 2006), but from one
reference it appears to be between one and three years. Several
studies also reported longer follow-up of safety outcomes.
Eight studies evaluated a range of dosages - low, medium, high
- or used a dose-escalation protocol (Creager 2011; Henry 2006;
Kibbe 2014; Kibbe 2016; Mohler 2003; Powell 2008; Rajagopalan
2003; Rajagopalan 2007). One study evaluated the same growth
factor in two treatments: one in a viral vector and one in a plasmid
vector (Makinen 2002). The remaining eight studies evaluated
one dose amount.
All studies administered treatment by intramuscular injection,
aside from Makinen 2002, which used an intra-articular route of
administration. Twelve studies solely evaluated treatments using
a plasmid vector (Belch 2011; Deev 2015; Deev 2017; Grossman
2007; Henry 2006; Kibbe 2014; Kibbe 2016; Kusumanto 2006;
Nikol 2008; Powell 2008; Powell 2010; Shigematsu 2010), four
using only a viral vector (Creager 2011; Mohler 2003; Rajagopalan
2003; Rajagopalan 2007), and, as stated above, one evaluating
both a viral vector and a plasmid vector (Makinen 2002).
Eight studies utilised a repeat dosage schedule for treatment (
Belch 2011; Deev 2015; Henry 2006; Kibbe 2016; Kusumanto
2006; Nikol 2008; Powell 2008; Powell 2010). Deev 2015, with
the shortest duration, treated participants at baseline and then
again on day 14. Kusumanto 2006 also undertook two dosages:
at baseline and at day 28. Powell 2008 and Powell 2010 treated
participants at baseline and at days 14 and 28. Belch 2011, Henry
2006, Kibbe 2016, and Nikol 2008 employed similar four-times
dosing schedules, around baseline and at days 14, 28, and 42,
with some variation. The remaining nine studies provided a single
treatment dose at baseline only.
Excluded studies
See Characteristics of excluded studies for the full list of excluded
studies with reasons.
We excluded a total of 16 studies with reasons. Six of these ex-
cluded studies overall met the inclusion criteria, but their diagno-
sis of PAD was insufficient and generally just described their pop-
ulation as having PAD (CLI or IC) without presenting any spe-
cific diagnostic criteria, such as ankle/toe pressures, exercise test-
ing, or angiography (Kalka 2000; Makinen 1999; NCT02544204;
Powell 2003; Rauh 1999; Talitskiy 2012). We excluded five
studies primarily because they were unlikely to be randomised,
and secondarily, because they did not meet the diagnostic cri-
teria for PAD (Gavrilenko 2015; Korpisalo 2015; Kusumanto
2001; Laitinen 1998; Morishita 2014). Two studies were non-ran-
domised (Anghel 2011; NCT02016755). Biggs 2009 did not de-
scribe the use of a comparison control group and provided insuf-
ficient evidence of PAD diagnosis. de Leeuw 2008 reported out-
comes only after 28 days, and for Gavrilenko 2008, it is unclear if
treatment fit within our inclusion criteria and if diagnosis of PAD
was insufficient.
Ongoing studies
We identified four ongoing studies (Fujino 2013; NCT00080392;
NCT00304837; NCT02144610). See Characteristics of ongoing
studies for details of the ongoing studies.
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Risk of bias in included studies
See Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Of the 17 included studies, six provided sufficient information
to indicate low risk of bias based on random sequence genera-
tion (Belch 2011; Deev 2017; Kusumanto 2006; Makinen 2002;
Nikol 2008; Shigematsu 2010). We rated most studies (10) as hav-
ing unclear risk because information on random sequence genera-
tion was insufficient (Creager 2011; Deev 2015; Grossman 2007;
Henry 2006; Kibbe 2014; Kibbe 2016; Powell 2008; Powell 2010;
Rajagopalan 2003; Rajagopalan 2007). We rated Mohler 2003 as
having high risk of selection bias because the protocol was altered
during the study due to participant refusal to receive placebo over
treatment, which could be evidence of improper random sequence
generation and allocation concealment.
For allocation concealment, three studies used adequate methods
(Belch 2011; Deev 2017; Shigematsu 2010). Thirteen studies pro-
vided insufficient detail to show whether researchers provided ade-
quate allocation concealment, and we rated them as having unclear
risk of bias (Creager 2011; Deev 2015; Grossman 2007; Henry
2006; Kibbe 2014; Kibbe 2016; Kusumanto 2006; Makinen
2002; Nikol 2008; Powell 2008; Powell 2010; Rajagopalan 2003;
Rajagopalan 2007). We rated Mohler 2003 as having high risk
of bias again for the reasons detailed above for random sequence
generation.
Blinding
Three studies provided sufficient information to show that their
blinding methods would ensure low risk of performance bias
(Belch 2011; Kusumanto 2006; Makinen 2002). Study investiga-
tors described 12 studies as double-blind and utilised a placebo
control but gave no supporting information that described how
blinding was maintained, for example, whether the placebo was
exactly the same in appearance as the treatment, so those adminis-
tering the treatment would not know the allocation (Creager 2011;
Grossman 2007; Henry 2006; Kibbe 2014; Kibbe 2016; Mohler
2003; Nikol 2008; Powell 2008; Powell 2010; Rajagopalan 2003;
Rajagopalan 2007; Shigematsu 2010). Two studies did not use a
placebo control, so we determined that they had high risk of per-
formance bias (Deev 2015; Deev 2017).
In evaluating detection bias, we found that five studies provided
sufficient information to show adequate blinding of outcome as-
sessors (Belch 2011; Makinen 2002; Nikol 2008; Powell 2008;
Powell 2010). Eleven studies did not provide sufficient informa-
tion regarding outcome assessors, and we rated them as having un-
clear risk for detection bias (Creager 2011; Deev 2015; Grossman
2007; Henry 2006; Kibbe 2014; Kibbe 2016; Kusumanto 2006;
Mohler 2003; Rajagopalan 2003; Rajagopalan 2007; Shigematsu
2010). We rated Deev 2017 as having high risk of detection bias
because investigators did not implement blinding procedures.
Incomplete outcome data
We rated nine studies as having low risk of attrition bias because
they clearly detailed the follow-up of all participants, or they in-
cluded sufficient intention-to-treat analysis methods (Belch 2011;
Grossman 2007; Kibbe 2016; Kusumanto 2006; Makinen 2002;
Nikol 2008; Powell 2008; Powell 2010; Rajagopalan 2003). We
rated seven studies as having unclear risk of attrition bias because
they did not report on follow-up of participants or they incurred
withdrawals without clear explanation or description of which
group they came from (Creager 2011; Deev 2015; Deev 2017;
Henry 2006; Kibbe 2014; Rajagopalan 2007; Shigematsu 2010).
We rated Mohler 2003 as having high risk of attrition bias because
study authors reported a large number of withdrawals from the
control group, leaving very few participants in this group.
Selective reporting
Eleven studies were at low risk of reporting bias, as they reported on
all outcomes specified in the protocol or Methods section (Creager
2011; Deev 2017; Grossman 2007; Kibbe 2016; Kusumanto
2006; Makinen 2002; Mohler 2003; Nikol 2008; Rajagopalan
2003; Rajagopalan 2007; Shigematsu 2010). We rated six studies
as having unclear risk of reporting bias, as they did not provide
enough information in the report to show low risk of reporting
bias, or they stated they would report on certain outcomes but
provided no, or insufficient, data on those outcomes (Belch 2011;
Deev 2015; Henry 2006; Kibbe 2014; Powell 2008; Powell 2010).
To assess publication bias, we generated funnel plots for outcomes
reported by more than 10 studies. We generated funnel plots for
the outcomes of amputation (above the ankle) and all-cause mor-
tality (Figure 4; Figure 5). We included 11 studies in the funnel
plot for amputation and found no visual evidence of publication
bias. We included 12 studies in the funnel plot for all-cause mor-
tality, and although the plot showed visual asymmetry, included
studies were too few to determine of there is evidence of publica-
tion bias. Studies included in both funnel plots were too few for
review authors to appropriately undertake hypothesis testing.
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Figure 4. Funnel plot of comparison: 1 Gene therapy versus no gene therapy control, outcome: 1.3
Amputation (above-ankle amputation of the index limb).
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Figure 5. Funnel plot of comparison: 1 Gene therapy versus no gene therapy control, outcome: 1.4 All-
cause mortality.
Other potential sources of bias
We rated 13 studies as having unclear risk of other bias, mainly
due to financial support form a commercial entity and/or unmet
sample size requirements (Belch 2011; Creager 2011; Deev 2015;
Deev 2017; Grossman 2007; Henry 2006; Kibbe 2014; Kibbe
2016; Kusumanto 2006; Makinen 2002; Nikol 2008; Powell
2008; Rajagopalan 2003). We rated Mohler 2003 as having high
risk of other bias in relation to points already made above regarding
serious changes in the protocol during the study. Powell 2010
had concerns with enrolment and stated in the ClinicalTrials.gov
report that there were “technical problems leading to unreliable or
uninterpretable data”. Therefore we rated this study as having high
risk of other bias. We also rated Rajagopalan 2007 as having high
risk of other bias because the investigators incorporated an open-
label phase after the initial blinded phase, during which several
placebo participants were rolled over to treatment and therefore
were counted twice in the analysis. We attempted to control for
this in the data that we included in this review by considering
participants as controls only if they had ever received placebo and
were not rolled over to treatment. We rated Shigematsu 2010 as
having high risk of other bias, as researchers encountered slow
recruitment and ended up curtailing their enrolment numbers and
conducting an interim analysis.
Effects of interventions
See: Summary of findings for the main comparison Gene
therapy compared to no gene therapy control for peripheral arterial
disease
For meta-analysis, if an included study evaluated different dosages
or types of gene therapy, we combined dosages or treatments into
a single treatment group. For outcomes for which we conducted
meta-analyses, we attempted to include data as close to 12 months’
follow-up as possible, as most included studies reported data at
this time point.
We did not include three studies in the meta-analysis (Henry 2006;
Kibbe 2014; Mohler 2003). Both Henry 2006 and Kibbe 2014
provided only published abstracts, which left us with insufficient
information regarding the study and study results. For Mohler
2003, we had serious concerns regarding the study’s high risk of
bias due to protocol changes (see Risk of bias in included studies),
so we chose not to include this study in the meta-analysis.
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Primary outcomes
Amputation-free survival (above-ankle amputation of the
index limb or death (any cause))
We included a total of four studies in the meta-analysis for ampu-
tation-free survival (Belch 2011; Kibbe 2016; Kusumanto 2006;
Nikol 2008). Due to high levels of heterogeneity, we utilised a
random-effects model and found no clear differences in outcomes
between gene therapy groups and control groups (odds ratio (OR)
1.68, 95% confidence interval (CI) 0.75 to 3.76; 756 participants;
I² = 73%; Analysis 1.1). We rated the evidence as moderate quality
due to evidence of heterogeneity.
Deev 2017 reported amputation-free survival of 96% in the treat-
ment group and 97% in the control group. We did not include
these data in the meta-analysis, as when we calculated participants
using the percentages supplied, the numbers of those reported to
have received an amputation and who had died were higher than
this calculated figure, meaning that this was not likely a true am-
putation-free survival outcome.
Ulcer healing
Seven studies reported on ulcer healing, but none of these studies
met the criteria of reporting ulcer healing by change in area in cm².
However, as several of these studies provided data on complete
ulcer healing, we chose to include them in the meta-analysis. We
included five studies in the meta-analysis of complete ulcer heal-
ing (Kibbe 2016; Nikol 2008; Powell 2010; Rajagopalan 2007;
Shigematsu 2010), which showed an OR of 2.16 (95% CI 1.02
to 4.59; 238 participants; P = 0.04; Analysis 1.2). We rated the
quality of the evidence as low because of risk of other bias in most
of the included studies that was due to poor study design or poor
execution of the protocol, and because the confidence interval was
quite wide, with few events, leading to imprecision. It should be
noted that only one of the five studies included in the meta-anal-
ysis independently demonstrated significant improvement in ul-
cer healing in the gene therapy group (Kibbe 2016), and when
we removed this study from the analysis, we noted no differences
between treatment groups.
Two additional studies reported on ulcer healing but did not meet
the criteria of describing their outcomes as “complete ulcer heal-
ing”. At 100 days, Kusumanto 2006 reported that seven of 21
ulcers in the treatment group showed a decrease in wound surface
area greater than 60% but no ulcers in the placebo group met this
criterion. Makinen 2002 reported ulcer healing in one of 18 par-
ticipants in the VEGF-adenovirus vector (VEGF-AdV) group, in
three of 17 in the VEGF-plasmid/liposome (VEGF-P/L) group,
and in two of 19 in the control group. Investigators provided no
further information on the definition of ulcer healing.
Quality of life (QoL)
Six studies reported on QoL as an outcome. One used solely the
Walking Impairment Questionnaire (WIQ), two used only the
Short Form-36 (SF-36) questionnaire, two evaluated QoL using
both the WIQ and the SF-36, and the sixth study evaluated QoL
using the RAND-36 questionnaire. Due to heterogeneity in col-
lection and reporting of data, we did not undertake meta-analy-
sis for this outcome. Most studies found no differences between
treatment groups in their measures of QoL; however, some stud-
ies found that all groups showed significant improvement during
the follow-up period. As with ulcer healing, we rated the findings
from this outcome as very low quality due to heterogeneity and
imprecision.
Using WIQ, Creager 2011 found no differences between groups
at baseline and at 3, 6, and 12 months for any of the compo-
nents measured: speed, claudication pain, or stair climbing. In
Grossman 2007, both treatment and control groups showed sig-
nificant improvement in WIQ speed and distance score from base-
line to follow-up and no between-group differences. Findings also
revealed no differences in SF-36 between groups at 90 or 180
days. Kusumanto 2006 utilised the RAND-36 questionnaire and
found no improvement in QoL when comparing the 165-amino-
acid isoform of VEGF (phVEGF165) versus control. Shigematsu
2010 reported at 12 weeks on the SF-36 domains of physical func-
tioning, role function (physical), bodily pain, general health per-
ception, vitality, social functioning, role function (mental), and
mental health. They found that the treatment group showed sig-
nificant improvement in bodily pain and mental health domains
over the placebo group. In Deev 2015, use of the SF-36 ques-
tionnaire revealed similar increases in treatment and control arms
for the physical health domain at six months. Researchers found
higher QoL scores regarding mental health in the control group
compared to the gene transfer treatment group. Last, Rajagopalan
2003, using both the SF-36 questionnaire and the WIQ, reported
improvements from baseline in both groups but no differences
between groups at 12 or 26 weeks.
Secondary outcomes
Amputation (above-ankle amputation of the index limb)
We included a total of 11 studies in the meta-analysis for ma-
jor amputation (Belch 2011; Deev 2015; Deev 2017; Kibbe
2016; Kusumanto 2006; Makinen 2002; Nikol 2008; Powell
2010; Rajagopalan 2003; Rajagopalan 2007; Shigematsu 2010).
Five studies reported on this outcome after 12 months of fol-
low-up (Belch 2011; Deev 2015; Kibbe 2016; Nikol 2008;
Rajagopalan 2007), three after six months (Deev 2017; Powell
2010; Rajagopalan 2003), two at three months (Makinen 2002;
Shigematsu 2010), and one at 100 days (Kusumanto 2006). Re-
sults show no clear differences between treatment groups in the
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fixed-effect model (OR 1.06, 95% CI 0.77 to 1.46; 1336 par-
ticipants; Analysis 1.3). It should be noted that two studies did
not clearly define their amputation outcomes (Deev 2015; Deev
2017). Results of the meta-analysis did not differ when we re-
moved these studies. We rated the quality of evidence on the out-
come of amputation as moderate due to possible heterogeneity
in outcomes between the largest study and the remaining studies.
Also, study authors reported low numbers of amputation events,
which could lead to imprecision, but we did not downgrade the
quality of evidence based on this because the confidence interval
was modestly narrow. We generated a funnel plot for this outcome
but found no evidence of reporting bias (Figure 4). However, it
should be noted that we included only 11 studies in the funnel
plot, making interpretation difficult and subjective.
Powell 2008 reported no differences in amputation at 12 months
but did not report the number of participants, and Mohler 2003
reported amputation in 6/13 (46%) of those in the treatment
group and in 1/2 (50%) participants in the control group at one
year.
All-cause mortality
We included 12 studies in the meta-analysis that evaluated all-
cause mortality (Belch 2011; Creager 2011; Deev 2015; Deev
2017; Kibbe 2016; Kusumanto 2006; Makinen 2002; Nikol 2008;
Powell 2008; Powell 2010; Rajagopalan 2003; Rajagopalan 2007).
Seven studies reported on mortality at 12 months (Belch 2011;
Creager 2011; Deev 2015; Kibbe 2016; Nikol 2008; Powell 2008;
Rajagopalan 2007), three at six months (Deev 2017; Powell 2010;
Rajagopalan 2003), and one at 100 days (Kusumanto 2006).
Makinen 2002 reported outcome evaluation at one and three
months after treatment but followed up with participants for sa-
fety outcomes, such as all-cause mortality, for a median of 24
months (range, four to 36 months). Results show no clear dif-
ferences in mortality between treatment groups in the fixed-ef-
fect model (OR 0.93, 95% CI 0.66 to 1.31; 1685 participants;
Analysis 1.4). We rated the quality of evidence for this outcome
as moderate due to possible heterogeneity, as the largest included
study reported a much higher rate of events compared with the
other included studies. As with amputation, events were few, but
we did not downgrade quality based on this, as the confidence
interval was sufficiently narrow. We also generated a funnel plot
for this outcome (Figure 5). Although visual analysis of the plot
revealed some asymmetry, details were insufficient to determine
if there was evidence of reporting bias. Studies included in the
funnel plot were too few to allow adequate hypothesis testing.
Shigematsu 2010 reported one death after 15 months but did
not state from which group it came. Mohler 2003 reported one
death among 13 (8%) participants in the treatment group and
zero deaths among 2 (0%) participants in the control group at one
year.
Ankle brachial index (ABI)
Only one study effectively reported change in ABI from baseline
after 25 weeks of follow-up (Nikol 2008). Results show no clear
differences between groups in the single study, and no overall as-
sociations can be drawn (mean difference (MD) 0.04, 95% CI -
0.07 to 0.15; 125 participants; Analysis 1.5). We rated the quality
of evidence for change in ABI as low because we included only a
single study, leading to serious imprecision.
Eleven more studies did report on ABI but not in a way that
was appropriate for adding data to the meta-analysis. Most stud-
ies found no differences between treatment groups and control
groups. Creager 2011 reported no differences between groups at
baseline and at 3, 6, and 12 months. Deev 2015 reported an in-
crease of 0.05 (P = 0.0009) in the treatment group at six months
and no change in the control group. Powell 2010 provided no
specific data on ABI in published references. However, data for
this study are available on the ClinicalTrials.gov website, which
reports ABI as the mean change in total ABI from baseline, but
the data are difficult to interpret and appear to represent the abso-
lute measurement, not the change score, so we have chosen not to
report these figures. Powell 2008 reported on toe-brachial index
(TBI) but found no differences at 12 months. Kibbe 2016 reported
that average ABI for each group was less than 0.5 at baseline and
noted no significant differences within or between groups at any
time point, nor with TBI. At 100 days, Kusumanto 2006 found
an absolute increase greater than 15% in ABI or TBI for at least
two time points among 7/21 (33%) in the treatment group and
1/17 (6%) in the control group. Makinen 2002 reported signifi-
cant improvements in the two treatment groups at three months
but noted similar improvements in control patients. Mohler 2003
found minimal or no improvements in ABI in four patients and
“delayed improvement” in two others. The only study to report
improvement in ABI in the treatment group, Deev 2017 reported
an ABI at baseline of 0.49 ± 0.01 and at six months of 0.61 ± 0.02
in the treatment group, and 0.51 ± 0.01 at baseline and 0.50 ±
0.01 at six months in the control group, with a between-treatment
group P value less than 0.001. After 12 months, Rajagopalan 2007
observed no differences but noted that measurement was not pos-
sible in all participants due to arterial calcification, amputation,
death, or early withdrawal. Shigematsu 2010 reported an initial
increase in mean ABI in the placebo group after 10 weeks but at
12 weeks observed no statistically significant differences between
groups.
Symptom scores
Two studies that we included in a meta-analysis reported change in
pain symptoms from baseline using a visual analogue scale (VAS).
Powell 2010 reported on pain using a 100-mm VAS scale at six
months, and Nikol 2008 used a 10-cm VAS scale at one year.
We converted the scale used by Powell 2010 to a 10-cm scale.
Meta-analysis showed no clear differences in pain scores between
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treatment groups (MD -0.22 cm, 95% CI -0.83 to 0.38; 152
participants; Analysis 1.6). We rated the quality of evidence as very
low due to risk of bias, as one of the included studies incurred
technical failures leading to poor data, moderate heterogeneity was
evident, and inclusion of only two studies resulted in evidence of
imprecision.
Shigematsu 2010 also evaluated pain symptom scores using VAS
but found no differences between groups. Powell 2008 reported no
difference in pain relief after 12 months. Makinen 2002, after three
months, reported resolution of pain in 1/18 (6%) participants in
the VEGF-AdV group and in 1/19 (5%) in the control group, with
none achieving resolution of rest pain in the VEGF-P/L group
(0%).
Claudication distance
Four studies reported claudication distances and/or times, but we
could not include these studies in a meta-analysis.
Creager 2011 observed no differences in peak walking time (PWT)
and claudication onset time (COT) between groups after six
months. Deev 2015 reported an increase in pain-free walking dis-
tance (PWD) of 110%, or a change of 149.5 metres, in the treat-
ment group, and a decrease of 1.5 metres from baseline in the
control group after six months. Deev 2017 also reported improve-
ment in PWD in the treatment group, with an increase of 176%
in the treatment group and a P value less than 0.001 for differences
between groups after six months. Rajagopalan 2003 reported in-
creases in PWT and COT in all groups after 26 weeks but no
differences between groups.
Subgoup and sensitivity analyses
At the outset of analysis, we found no substantial clinical or
methodological heterogeneity between studies included in the
meta-analysis that was not already identified through planned sub-
group or sensitivity analysis.
Subgroup analysis
To evaluate the effects of different subgroups on analyses, we in-
cluded the results of four separate subgroup analyses, which con-
sisted of (1) subgroup by PAD classification - IC or CLI; (2) sub-
group by dosage schedule - single dosage or repeat dosages; (3)
subgroup by vector type - plasmid or viral; and (4) subgroup by
gene type encoded in the treatment. For ease of incorporating these
results, we created a separate comparison for each subgroup with
the included outcomes. We evaluated an outcome in the subgroup
analysis if it included at least three studies that were not all of the
same subgroup category. We did not carry out subgroup analysis
for single-gene versus multi-gene treatments, as all included stud-
ies evaluated only single-gene treatments. We did not carry out
subgroup analysis for treatment route, as all but one study utilised
intramuscular injections, and we performed no subgroup analysis
based on studies including participants with diabetes mellitus, as
all studies included participants with diabetes and did not report
their data based on diabetes status.
Comparison of participants with IC versus those with CLI re-
vealed no differences between subgroups in major amputation (P
= 0.79) or all-cause mortality (P = 0.69) (Analysis 2.1; Analysis
2.2). Comparison of studies that evaluated single dosage schedules
versus repeat dosages showed no differences between subgroups
for both major amputation (P = 0.44) and all-cause mortality (P
= 0.23) (Analysis 3.1; Analysis 3.3). We noted evidence of superi-
ority of a repeated dosage schedule over a single dosage schedule
for complete ulcer healing, but this was most likely due to the
fact that most of the studies that included this outcome utilised
a repeat schedule (Analysis 3.2). Overall we noted no differences
between subgroups (P = 0.51). Analysis revealed no differences
between subgroups for comparisons of plasmid versus viral vectors
in major amputation (P = 0.40) nor all-cause mortality (P = 0.32)
(Analysis 4.1; Analysis 4.2). In subgroup analysis of differences
among genes encoded for in treatment groups, the single study
that evaluated a VEGF-encoding treatment showed evidence of
improvement in the treatment group over the control group for
the outcome of amputation-free survival, but we cannot draw an
overall conclusion based on the findings of a single study. The
FGF- and HGF-encoding treatments showed no differences from
control (Analysis 5.1). Overall we found no differences between
subgroups (P = 0.43). We also noted no differences for the out-
comes of major amputation and all-cause mortality between dif-
ferent gene treatment types (P = 0.55 and P = 0.79, respectively)
(Analysis 5.3; Analysis 5.4). Studies that utilised HGF-encoding
vectors provided evidence of complete ulcer healing, and the sin-
gle studies that evaluated FGF and HIF-1α provided insufficient
data to permit any conclusions at this time. Overall results show
no differences between subgroups (P = 0.24) (Analysis 5.2).
Sensitivity analysis
We carried out sensitivity analysis on outcomes from the primary
comparison (non-subgroup) if at least three studies reporting an
outcome remained after sensitivity analysis, by excluding (1) stud-
ies that were particularly large or long; (2) cross-over trials, clus-
ter-randomised trials, and multiple observations for the same out-
come; and (3) any RCTs that we judged to be at high risk of bias
across one or more of the domains evaluated. Upon conducting
sensitivity analysis based on these criteria, we found no change in
any of the results, which included outcomes of amputation-free
survival, major amputation, and all-cause mortality.
We performed an additional sensitivity analysis to assess any overt
impact that phase III trials may have had on the analysis. For this
sensitivity analysis, we removed the two phase III RCTs - Belch
2011 and Deev 2015 - and found that with only three studies re-
maining, amputation-free survival was increased in the gene ther-
apy group as compared with the control group (OR 2.48, 95% CI
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1.39 to 4.41; 231 participants; P = 0.002). For the same sensitiv-
ity analysis, the outcomes of amputation and all-cause mortality
showed no differences when phase III trials were removed.
We also conducted sensitivity analysis by removing studies that
overall met our inclusion criteria and included diagnostic crite-
ria for PAD, but for which the diagnostic criteria may not have
matched precisely those laid out in the protocol of this review. We
removed four studies from the analysis (Deev 2015; Kibbe 2014;
Powell 2008; Powell 2010). When we excluded these studies from
the analysis, we found no differences from the findings of original
analyses.
D I S C U S S I O N
Summary of main results
We included in this review a total of 17 randomised controlled tri-
als, totaling 1988 randomised participants. Included studies rep-
resent a varied range of gene therapy types, with most encoding
for some kind of growth factor. Most studies compared gene ther-
apy versus placebo, but two studies compared gene therapy versus
conservative treatment.
Evidence from meta-analysis showed no clear differences between
gene therapy and control for amputation-free survival, major am-
putation, and all-cause mortality, although evidence revealed sta-
tistical heterogeneity in the amputation-free survival outcome, for
which we included only four studies. Limited evidence suggests
improved complete ulcer healing in the gene therapy group. We
could include in the analysis only one study that evaluated the
ankle brachial pressure index (ABI), finding no evidence of a clear
difference between groups. We included in the analysis two stud-
ies that reported pain symptom scores obtained on a visual ana-
logue scale (VAS) and found no clear differences between treat-
ment groups. We could not combine studies for meta-analysis for
the outcomes of quality of life (QoL) and claudication distance, al-
though several studies did report on these outcomes. See Summary
of findings for the main comparison for further results for the
main outcomes.
Overall completeness and applicability of
evidence
We included 17 trials in this review. Even with this number of
included studies, only a few or no studies assessed many of the
outcomes of this review, including two of the three primary out-
comes - amputation-free survival and quality of life - and the sec-
ondary outcomes of ABI, symptom score, and claudication dis-
tance. However, a sufficient number of studies reported outcomes
of major amputation and all-cause mortality to permit a conclu-
sion.
Although we found possible evidence of improved ulcer healing
in the gene therapy group, this noted improvement should be ac-
cepted with awareness of the possibility that informative censoring
bias may be affecting the other outcomes. This form of bias occurs
when censoring time distribution is not independent of the time
to event distribution, in this case, ulcer healing (i.e. participants
who experience ulcer healing may be censored sooner), thereby
missing out on subsequent deaths or amputations. Good study
design and analysis would take this type of bias into account, but
it is unclear to the review authors if we can fully accept these out-
comes as free of informative censoring.
We applied stringent inclusion criteria surrounding the diagnosis
of peripheral arterial disease (PAD) based on objective measures of
disease. The included studies do evaluate a wide range of gene ther-
apy types, mainly involving growth factor-encoding genes. Most
of the included studies evaluated participants with more severe
PAD, with a diagnosis of critical limb ischaemia (CLI), but several
studies also evaluated those with intermittent claudication (IC)
without evidence of more severe disease. This review does not ad-
dress use of cell-based therapy nor use of direct angiogenic growth
factors.
To fully explore the differences between study methods and par-
ticipants, we conducted subgroup analyses by PAD severity (IC or
CLI), by dosage schedule (single or repeat dosages), by vector type
(plasmid or viral), and by the encoding genes involved in gene
therapy. We found no evidence that any subgroups were more ef-
fective for the outcomes evaluated, which were limited mainly to
amputation and all-cause mortality. This type of subgroup analy-
sis is critical for determining whether specific types of gene ther-
apy or specific participant subgroups derive greater benefit from
treatment than others; however, this review provides no evidence
of such differences. Researchers are interested in evaluating dif-
ferences in other haematological parameters between responders
to treatment and non-responders, which could yield greater detail
on subgroups of interest, but this goal is outside the scope of the
present review (Korpisalo 2015; Talitskiy 2012).
Quality of the evidence
Risk of bias was generally unclear due to lack of detailed reporting
(Figure 2; Figure 3). This was especially true for selection bias, per-
formance bias, and detection bias. Regarding performance bias,
15 of the 17 studies utilised a placebo and were described as dou-
ble-blind, but most of these studies did not clarify how blinding
was maintained. We rated the two studies that were not blinded
as having high risk of performance bias. Risk of attrition bias and
reporting bias was mainly low, but several studies did not clar-
ify findings on follow-up of their participants, and some studies
assessed outcomes that were not reported on, although evidence
shows they were included in the protocol. Commercial groups that
21Gene therapy for peripheral arterial disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
manufactured the treatment used in the trial supported all of the
included studies, and not all reports clearly stated the role of the
sponsor in data collection, interpretation, and reporting. We rated
these studies as having unclear risk of other bias. Several studies
also showed protocol differences that are indicative of bias, so we
rated them as having high risk of other bias, including protocol
deviations and counting participants twice for a single analysis.
Quality of the evidence, as evaluated by GRADE, ranged from
moderate to very low. More included studies reported on outcomes
rated as moderate (amputation-free survival, amputation, all-cause
mortality), so we noted little imprecision but found evidence of
heterogeneity. We evaluated outcomes rated as low and very low
(ulcer healing, QoL, ABI, pain symptom scores) through meta-
analysis but found few or no data and identified issues related to
risk of bias and heterogeneity. See Summary of findings for the
main comparison.
Potential biases in the review process
To minimise potential bias, we undertook a comprehensive search
of the literature, with two review authors reviewing all studies for
inclusion. Two review authors extracted data, using a predefined
data extraction format. However, the possibility remains that rel-
evant literature and data, published or unpublished, were missed
in the study selection and data extraction processes.
One study - Rajagopalan 2007 - incorporated a randomised, dou-
ble-blind, placebo-controlled first phase of the study with an open-
label phase, after which several placebo participants were rolled
over to treatment and were therefore counted twice in the analysis.
In the first phase, researchers randomised 28 participants, with
seven participants receiving placebo. For the open-label phase, in-
vestigators added 10 participants for treatment and rolled over
three placebo participants from the initial study to receive treat-
ment. We initially planned to include only those enrolled in the
first phase, but this was not possible because of reporting issues.
Therefore, for our analysis, we included, where possible, control
participants who only ever received placebo and were not rolled
over, as well as those not initially treated with placebo. This is ev-
ident in the major amputation outcome, for which study authors
reported 10 cases of major amputation in the treatment group;
one of those cases was initially a placebo-treated participant, so we
did not include this case in our analyses.
We imputed several outcomes using data provided by included
studies; both Nikol 2008 and Belch 2011 provided a combined
death and/or amputation outcome that was then inverted to gen-
erate an amputation-free survival outcome. Nikol 2008 and Powell
2010 provided a change in ABI and VAS with a standard error
of the mean (SEM), which was converted to standard deviation
(SD) using the formula: SD = SEM *
√
n. These methods should
not lead to biased data but should be considered when data are
interpreted.
Four included studies did not fully meet our criteria for PAD
diagnosis. However, these four studies included various measures
and descriptions of vascular disease that we deemed appropriate
to include, as they most likely evaluated the same population as
studies that fully met inclusion criteria (Deev 2015; Kibbe 2014;
Powell 2008; Powell 2010). We performed sensitivity analysis by
excluding these studies from their respective meta-analyses, and we
found no differences in results as compared with original analyses.
For analyses in this review, we utilised fixed-effect models for meta-
analysis unless we found strong statistical evidence of heterogene-
ity, using the I² statistic as a reference. Analysis could also be un-
dertaken solely with random-effects models to account for clini-
cal heterogeneity within studies. We will explore this method in
future updates.
Agreements and disagreements with other
studies or reviews
A systematic review and meta-analysis published in 2013 utilised
similar inclusion and exclusion criteria (Hammer 2013). The 12
included studies follow closely studies included in this review,
and review authors also found no differences between treatment
groups for the outcomes of amputation and all-cause mortality.
Hammer 2013 did include the outcome of ulcer healing in their
meta-analysis and found no differences between treatment groups
in the number of healed ulcers. In our review, we used different
criteria to evaluate ulcer healing and found evidence of possible
improved complete ulcer healing in the gene therapy treatment
group. Also, the single study in our review showing evidence of
improved ulcer healing in the treatment group - Kibbe 2016 - was
not yet published at the time of the Hammer 2013 meta-analysis.
A recently published Cochrane Review evaluated the use of any
growth factors for angiogenesis in PAD (Gorenoi 2017). Our re-
view considered all types of gene therapy but excluded trials in-
volving direct growth factor delivery (treatment with direct growth
factor protein as opposed to a viral or plasmid vector containing
genes encoding for a growth factor) or cell therapy. Many of the
studies included in the Gorenoi 2017 review overlap with the stud-
ies included in our review. Gorenoi 2017 also found no differences
in major amputation or mortality between treatment groups.
A review and meta-analysis from 2008 included five studies, four
of which we also included in this review and one that we considered
not relevant, as it utilised a direct growth factor protein for treat-
ment (Ghosh 2008). This meta-analysis found no differences in
peak walking time (PWT), claudication onset time (COT), ABI,
or adverse events between treatment and control groups. This re-
view evaluated low-dose and high-dose treatments against control
separately.
De Haro 2009 produced a meta-analysis of phase II randomised
studies evaluating gene therapy, as well as cell therapy, in people
with PAD. Of their six included studies with 543 participants,
only three met the inclusion criteria for our review. Review authors
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found a statistically significant improvement in the treated group
for the outcome “overall therapeutic angiogenesis efficacy” (odds
ratio (OR) 1.437, 95% confidence interval (CI) 1.029 to 2.005),
but it is unclear what was being measured. This meta-analysis also
showed no difference in mortality and, similar to Ghosh 2008,
found no differences in overall treatment-related adverse events.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate-quality evidence shows no clear differences in effective-
ness among people with PAD between gene therapy and no gene
therapy for the outcomes of amputation-free survival, major am-
putation, and all-cause mortality. Low-quality evidence suggests
that gene therapy may improve complete ulcer healing when com-
pared with control, but these findings have limitations. Very little
or no evidence is available regarding other important outcomes
such as quality of life and pain symptom scores.
Implications for research
Further research must be undertaken to assess the effectiveness of
gene therapy in people with PAD with focus on outcomes such
as ulcer healing, quality of life, ABI, and claudication distance.
Although several of the studies included in this review did report
on these outcomes, researchers must give more thought to ways of
disseminating these data, such as providing accurate change from
baseline measures with measures of error, so data can be evalu-
ated and compared appropriately through methods such as meta-
analysis. We found evidence of possible improvement in complete
ulcer healing in the gene therapy group, which must be further in-
vestigated through the use of more robust measures of ulcer heal-
ing. Further evidence is needed around proper dose and timing
protocols and regarding differences in treatment of patients with
CLI versus IC.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belch 2011
Methods Study design: multi-centre phase III double-blind placebo-controlled RCT
Intention-to-treat: yes
Countries: 30 countries
Participants Number randomised: N = 525 (NV1FGF n = 259; placebo n = 266)
Losses to follow-up and withdrawals: N = 0
Age (mean years (range)): 70 years (50 to 95) (NV1FGF 71 (50 to 95); placebo 69 (50
to 92))
Gender (M): 70% (NV1FGF 69%; placebo 70%)
Inclusion criteria: age > 50 years; CLI with ischaemic lesions (Fontaine stage IV) with
diagnosis confirmed by at least 1 haemodynamic measurement (ankle pressure < 70
mmHg, toe pressure < 50 mmHg, or TcPO < 30 mmHg) and by 1 imaging technique
(angiography or doppler examination), and confirmed by vascular surgeons that partici-
pant was unsuitable for revascularisation; and to justify this decision to the independent
adjudication panel, patent femoral artery inflow assessed by digital angiography, magnetic
resonance, or CT angiography (doppler if previous angiography is available) < 6 months
before first administration of study treatment; negative screening for cancer (including
family history, complete physical examination of every system organ including the skin,
haematological blood testing, chest radiography, stool haemoccult test, measurement of
prostate-specific antigen for men, and mammography and Papanicolaou test for women,
and any investigation required by national guidelines for cancer screening)
Exclusion criteria: previous major amputation of the leg to be treated; planned major
amputation within the first month after randomisation; infected gangrene affecting the
forefoot evidenced by imaging (radiography); CLI caused by Buerger’s disease; ulcers
from venous or neuropathic origin if not associated with at least 1 ulcer of arterial
origin; successful revascularisation procedure of the lower leg or any other successful
treatment of the leg to be treated < 3 months before randomisation; uncontrolled blood
pressure defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥
110 mmHg; severe comorbid disorder, not expected to survive longer than 12 months;
acute cardiovascular events within 3 months before randomisation; active or proliferative
retinopathy and severe macular oedema; previous or present history of malignant disease,
other than basal cell carcinoma and cervical carcinoma in situ, within the past 5 years;
previous malignant disease with relapse or therapy within the past 5 years; previous
treatment with systemic growth angiogenic factors or with stem cell therapy; women
pregnant or breastfeeding, or of childbearing potential not protected by an effective
contraceptive method of birth control; men not following effective contraceptive method
with their partner of childbearing potential during the study
Interventions Treatment: NV1FGF, 0.2 mg/mL, eight 0.5-mg intramuscular injections in the index leg
(affected leg; if disease affected both legs and both were unsuitable for revascularisation,
the leg with the lowest ABI or TBI), 4 injections into the calf (anterior and posterior
regions) and 4 into the thigh on days 1, 15, 29, and 43; injection sites selected according
to an accessible good striated muscle mass and as close as possible to areas of known
collateral blood flow development
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Belch 2011 (Continued)
Control: placebo, given in the same manner as treatment
Outcomes Follow-up times: 2, 4, and 6 weeks and 2, 6, 9, and 12 months (exploratory extended
safety assessment at 18, 24, 30, and 36 months)
Outcomes: Amputation, Death, Skin lesion status, Pain intensity at rest (VAS), Func-
tionality and general health assessment - ambulatory function and residential status for
patients (Deneuville questionnaire) and overall QoL (using EuroQoL), Admittance to
hospital for amputation and other CLI-related issues; ABI; TBI; safety assessment (ad-
verse events, subjective symptoms, vital signs, ECG, ophthalmic exam, blood tests)
Notes Study period: recruitment from 1 December 2007 to 31 July 2009
NCT00566657
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a central interactive voice response
system by block size of 4 and stratified by
diabetes status and country; “generated by
an electronic technique”; randomised 1:1
Allocation concealment (selection bias) Low risk Used a central interactive voice response
system for randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Visually identical matching placebo; “In-
vestigators, patients and study teams were
masked to treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Investigators, patients and study teams
were masked to treatment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants were lost to follow-up and
all discontinued clearly reported; ITT anal-
ysis performed
Selective reporting (reporting bias) Unclear risk Did not report ABI/TBI; pain severity by
VAS; QoL outcomes, which were indicated
in the Methods; the additional publication
- Van Belle 2011 - does mention baseline
geographical and diabetes status but does
not provide the data in a meaningful way
Other bias Unclear risk Funded by Sanofi-Aventis; the sponsor was
responsible for data monitoring, data col-
lection, and data analysis but had no role in
data interpretation or writing of the report
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Creager 2011
Methods Study design: multi-centre prospective double-blind placebo-controlled parallel-group
RCT
Intention-to-treat: no; utilised “efficacy set”, which includes all patients who were ran-
domised and had at least 1 post-randomisation treadmill exercise test; utilised last ob-
servation carried forward methods
Countries: USA (27 sites), UK (4 sites), Germany (4 sites)
Participants Number randomised: total N = 289 (low-dose HIF-1α n = 74; mid-dose HIF-1α n =
74; high-dose HIF-1α n = 65; placebo n = 76); “efficacy set”: N = 273 (low-dose HIF-
1α n = 69; mid-dose HIF-1α n = 71; high-dose HIF-1α n = 62; placebo n = 71)
Losses to follow-up and withdrawals: not reported; only report n = 16 with no follow-
up treadmill tests
Age (mean years ± SD): 68.4 ± 8.4 (low-dose 65.7; mid-dose 68.8; high-dose 66.7;
placebo 66.2)
Gender (M): low-dose 78.4%; mid-dose 78.4%; high-dose 72.3%; placebo 72.4%
Inclusion criteria: men and women 40 to 80 years of age; bilateral atherosclerotic PAD
and IC ascertained by resting ABI ≤ 0.90 in the index leg (if arteries non-compressible,
TBI ≤ 0.70); PAD in non-index leg confirmed by resting ABI ≤ 0.90, reduction in
ABI by ≥ 20% after exercise if ABI at rest was > 0.90, or stenosis ≥ 50% as evidenced
by duplex ultrasonography, magnetic resonance angiography, or computed tomographic
angiography; catheter-based angiography for diagnosis if necessary; PWT between 1 and
12 minutes on a graded exercise treadmill test and confirmation of PAD as a reason for
claudication by a decrease in ABI in the index leg or ≥ 20% immediately after exercise;
stable claudication symptom for at least 6 months; smoking status; exercise habits; other
medical therapy for claudication; stable for 3 months before enrolment
Exclusion criteria: aortoiliac disease limiting the inflow of blood to areas of the limb
that were to receive study treatment injections (thighs and calves); type 1 diabetes mel-
litus; CLI defined as the presence of rest pain, non-healing ulcers, or tissue loss; PAD-
specific surgical revascularisation within 6 months or an endovascular procedure within
3 months of enrolment; conditions other than PAD that could confound assessment
of walking time such as angina, congestive heart failure, or chronic lung disease; cancer
within the previous 5 years and not current with American Cancer Society-recommended
cancer screening tests; proliferative diabetic retinopathy and clinically significant abnor-
mal haematological, renal, and hepatic laboratory values
Interventions Treatment:
Low-dose HIF-1α - 2 × 10 viral particles Ad2/HIF-1α/VP16, 20 intramuscular injec-
tions to each leg (100 µL per injection for a total of 2.0 mL per limb) at predefined sites
in the thigh (11 injections) and calf (9 injections)
Mid-dose HIF-1α - 2 × 10¹ viral particles Ad2/HIF-1-α/VP16, as in manner of treat-
ment above
High-dose HIF-1α - 2 × 10¹¹ viral particles Ad2/HIF-1-α/VP16, as in manner of treat-
ment above
Control: placebo, phosphate-buffered saline, 10% sucrose, and 0.02% polysorbate 80,
given in the same manner as treatment above
Outcomes Follow-up times: 3, 6, and 12 months
Outcomes: PWT and COT (graded treadmill test, modified Gardner protocol), ABI,
QoL (WIQ)
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Creager 2011 (Continued)
Notes Study period: not reported
NCT00117650
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to de-
termine random sequence generation; ran-
domisation at a ratio of 1:1:1:1 per treat-
ment group
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how saline
placebo was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 16/289 participants not included in effi-
cacy set due to not having a treadmill test
after baseline, but no discussion of other
losses or dropouts
Selective reporting (reporting bias) Low risk All outcomes listed in the ClinicalTrials.gov
protocol reported on appropriately
Other bias Unclear risk Power calculation required 75 participants
in each arm for 80% power to detect a treat-
ment effect of 1.5 minutes in the 26-week
change from baseline in PWT
Data were collected and analysed by the
sponsor, Genzyme Corp., manufacturer of
Ad2/HIF-1α/VP16
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Deev 2015
Methods Study design: multi-centre phase IIb/III open-label RCT
Intention-to-treat: not specified; for PWD, n = 5 in treatment group and n = 1 in control
group had amputation before enrolment and therefore could not perform treadmill test;
reported “analyzed population in the study included 94 patients: 70-in the test group
and 24-in the control group”
Country: Russia
Participants Number randomised: N = 100 (pCMV-vegf165 n = 75; control n = 25)
Losses to follow-up and withdrawals: not specified
Age (mean years ± SD): pCMV-vegf165 67.8 ± 9.0; control 70.9 ± 7.8
Gender (M): pCMV-vegf165 80%; control 80%
Inclusion criteria: inclusion decision made by a team of vascular surgeons and radiol-
ogists based on angiographic and echographic findings, history of the disease, previous
procedures, and concomitant pathology; age > 40 years; history of stable claudication for
at least 3 months; stage II to III chronic ischaemia according to Fontaine classification;
absence of haemodynamically significant (> 70%) stenosis of the aortoiliofemoral arterial
segment or (if present) a patent proximal bypass graft if revascularisation surgery was
performed no earlier than 3 months before inclusion in the study; satisfactory patency of
the deep femoral artery in the presence of haemodynamically significant femoropopliteal
arterial lesions; presence of haemodynamically significant stenosis (stenosis > 70% and/
or occlusion); diffuse lesions of the anterior and/or posterior tibial arteries; voluntary
informed consent signed
Exclusion criteria: CLI of non-atherosclerotic genesis (autoimmune disorders, Buerger’s
disease, congenital abnormalities, vascular injuries, etc.); stage IV chronic ischaemia
according to Fontaine classification; severe concomitant pathology with life expectancy
< 1 year; infectious disease; history of cancer or suspected malignancy; decompensated
diabetes mellitus
Interventions Treatment: pCMV-vegf165 (Neovasculgen) - intramuscular injection of 1.2 mg of
pCMV-vegf165, administered at 4 to 5 injection sites in the lower and middle thirds of
the posterior part of the calf; a second 1.2-mg injection administered 14 days after first
treatment, in conjunction with standard treatment
Control: standard treatment only
Outcomes Follow-up times: 6 months, 1 and 2 years
Outcomes: PWD, ABI, Blood flow velocity; Additionally QoL (SF-36) at 6 months
only; Safety (adverse events, blood and urine lab tests, chest X-rays, and abdominal
echography)
Notes Study period: protocol approved April 2010
NCT03068585
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine adequate random sequence genera-
tion; randomised to 2 groups at a ratio of
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Deev 2015 (Continued)
3:1
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not undertaken and not feasible
due to the nature of treatment and control
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses and withdrawals not reported
Selective reporting (reporting bias) Unclear risk ClinicalTrials.
gov protocol states researchers will evaluate
transcutaneous oximetry, but this is not re-
ported in the results
Other bias Unclear risk With 3:1 randomisation, there were only
25 participants in the control group, which
limited the subgroup analysis; as stated in
the report, no participants in the control
group had stage IIa disease
Sample size calculation estimated 28 partic-
ipants in each group to detect a 0.75 stan-
dardised difference (80% power)
Several study authors are employees of the
OJSC Human Stem Cell Institute, which
funded the study
Deev 2017
Methods Study design: multi-centre open controlled prospective comparative RCT
Intention-to-treat: not reported
Countries: Russia, Ukraine
Participants Number randomised: N = 210 (pl-VEGF165 n = 150; control n = 60)
Losses to follow-up and withdrawals: not reported
Age (mean years ± SD): pl-VEGF165 62.7 ± 9.4; control 68.9 ± 7.1
Gender (M): pl-VEGF165 85%; control 74%
Inclusion criteria: people age ≥ 40 years with diagnosis of IC and CLI of atherosclerotic
genesis that correlated with stage II to III according to Fontaine-Pokrovsky classification
(pain-free walking distance < 200 m and resting pain); unsuitable for surgical and en-
dovascular vessel reconstruction; signed consent form
Exclusion criteria: any disease that can, in the opinion of the treating physician, affect
the outcome of the study; ulcerous-necrotic changes in limb tissues; addictive disorders or
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Deev 2017 (Continued)
substance abuse; pregnancy or nursing; all other exclusion criteria listed in the summary
of product characteristics
Interventions Treatment: pl-VEGF165 (Neovasculgen) - 2 × 1.2 mg intramuscular injections for a
total dose of 2.4 mg, administered at 4 to 5 injection sites in the lower and middle thirds
of the posterior part of the calf muscle
Control: conservative therapy without prostaglandins and prostacyclins
Outcomes Follow-up times: 3 months and 6 months
Outcomes: PWD, Adverse drug reactions (using ECG, blood haematology and bio-
chemistry, a coagulation panel, and urinalysis), ABI, blood flow linear velocity, TcPO
, Mortality, Amputation
Notes Study period: completed January 2017
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a computer-gen-
erated block randomisation list (block size
5) with consecutively numbered and sealed
envelopes
Allocation concealment (selection bias) Low risk Used sealed envelopes prepared in advance
of the study by a researcher; local trial co-or-
dinator who enrolled patients and assigned
them to groups was unable to access the
randomisation list
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label, no blinding; high chance of
leading to bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts or withdrawals reported
Selective reporting (reporting bias) Low risk All outcomes from ClinicalTrials.gov pro-
tocol reported
Other bias Unclear risk Funding from Human Stem Cells Institute
OJSC, Moscow, Russia
No reporting of results from the post-mar-
keting phase
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Grossman 2007
Methods Study design: multi-centre phase II double-blind placebo-controlled trial
Intention-to-treat: not specified
Country: USA
Participants Number randomised: N = 105 (VLTS-589 n = 52; control n = 53)
Losses to follow-up and withdrawals: N = 7 withdrew (VLTS-589 n = 4; control n
= 3); reasons: death n = 3, withdrawal of consent n = 1, loss to follow-up n = 2, pre-
existing condition n = 1
Age (mean years ± SD): 67.7 ± 8.95 (VLTS-589 67.3 ± 8.16; control 68.1 ± 9.73)
Gender (M): 84.8% (VLTS-589 88.5%; control 81.1%)
Inclusion criteria: between the ages of 40 and 81; significant bilateral infrainguinal PAD
as assessed by duplex ultrasound, magnetic resonance angiography, computed tomogra-
phy angiography, or cineangiography within 6 months before screening; stable exercise
limiting IC of the lower extremities of > 2 months’ duration with a diagnosis of PAD
confirmed with ABI ≤ 0.80 in both lower extremities or TBI < 0.70
Exclusion criteria: significant in-flow disease defined as > 50% stenosis in the distal
aorta, common iliac, external iliac, or common femoral arteries; CLI, change in claudica-
tion symptoms within 2 months; terminated the treadmill for reasons other than claudi-
cation; lower extremity percutaneous intervention within 2 months; lower limb surgical
revascularisation within 6 months before study entry or participation in a structured ex-
ercise treatment protocol within 30 days of the study; unstable angina; recent MI; recent
coronary artery bypass grafting or coronary percutaneous intervention; stroke; conges-
tive heart failure or deep venous thrombosis; history of malignant neoplasm within the
past 5 years or presence of proliferative retinopathy; women of reproductive potential
required to have a negative pregnancy test at the time of study drug administration
Interventions Treatment: 42 mg VLTS-589 (Del-1) - an investigational, non-viral, plasmid-based ther-
apeutic comprising a plasmid (pDL1680) expression system formulated with poloxamer
188 - delivered via 21 percutaneous intramuscular injections of 2 mL each
Control: placebo, poloxamer 188 alone, delivered in the same manner as treatment
Outcomes Follow-up times: 30, 90, and 180 days
Outcomes: PWT (Gardner exercise treadmill test protocol), ABI, COT, QoL (WIQ and
SF-36 v2)
Notes Study period: June 2003 to June 2005 - estimated dates
NCT00068133
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine random sequence generation
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how saline
placebo was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Seven dropouts clearly described and simi-
lar between groups
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Sponsored by Valentis, Inc.
Henry 2006
Methods Study design: multi-centre phase II double-blind placebo-controlled randomised study
Intention-to-treat: not reported
Country: USA
Participants Number randomised: N = 71
Losses to follow-up and withdrawals: not reported
Age (mean years ± SD): not reported
Gender (M): not reported
Inclusion criteria: 45 years old; informed consent signed before proceeding with any
study procedure; severe PAD; trophic lesions with no signs of healing for at least 2 weeks
before first study treatment administration; objective evidence of peripheral vascular
disease in the diseased limb on 2 consecutive examinations performed at least 1 week
apart; demonstration or documentation of total occlusion of the affected limb of 1
or more iliac, superficial femoral, popliteal, and/or 1 or more infrapopliteal arteries as
assessed by angiography or magnetic resonance angiography; mean resting supine TcPO
of the foot ≤ 40 mmHg based on 2 separate measures performed at least 1 week apart;
poor/not candidates for revascularisation
Exclusion criteria: previous or current history of malignant disease; positive cancer
screening; successful lower extremity surgery; planning to undergo amputation of target
limb within 1 month following first administration of study treatment; history of severe
renal failure; creatinine > 2.0 mg/dL or estimated creatinine clearance < 30 mL; serious
concomitant medical conditions not adequately controlled; Buerger’s disease; on dialysis;
active proliferative retinopathy with stroke or neurological deficit presumed to be due to
stroke within 3 months before first administration of study treatment; previous treatment
with any angiogenic growth factor; positive serology for HIV 1 or 2; participation in
clinical trials of non-approved experimental agents within 4 weeks before study entry
Interventions Treatment: NV1FGF, 1 of 5 treatment regimens of 2 to 16 mg, delivered by 8 intra-
muscular injections in the affected leg every 2 weeks for 4 sessions
Control: placebo
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Outcomes Follow-up times: not reported, but 1 reference suggests between 1 and 3 years
Outcomes: TcPO , Ulcer healing
Notes Study period: June 2002 to July 2005
NCT00798005
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine random sequence generation
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how placebo
was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information reported on study popula-
tion during follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information to determine se-
lective reporting bias
Other bias Unclear risk Sponsored by Sanofi
Kibbe 2014
Methods Study design: multi-centre phase IIa double-blind placebo-controlled randomised trial
Intention-to-treat: not reported
Country: not reported
Participants Number randomised: N = 48
Losses to follow-up and withdrawals: not reported
Age (mean years ± SD): 58.6 ± 13.7
Gender (M): 88%
Inclusion criteria: CLI (Rutherford 4 or 5); poor candidates for surgical revascularisa-
tion; receiving stable medical therapy; ankle systolic pressure ≤ 70 mmHg or toe systolic
pressure ≤ 50 mmHg
Exclusion criteria: not reported
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Interventions Treatment: plasmid stromal cell-derived factor-1 (pSDF-1), 4 cohorts, single set of direct
intramuscular injections (8 or 16) to the ischaemic limb at escalating doses of 1 mg/mL
pSDF-1 (4, 8, 8, or 16 mg)
Control: placebo
Outcomes Follow-up times: 12 months
Outcomes: QoL (SF-36), VAS, Rutherford class, Time to first/Number of amputations,
Wound healing, Survival
Notes Study period: enrolment completed July 2013
Only conference proceedings available from interim report; stated 12-month data would
be available September 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine random sequence generation
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how placebo
was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information reported on study popula-
tion during follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information to determine se-
lective reporting bias
Other bias Unclear risk Support from Juventas Therapeutics
Kibbe 2016
Methods Study design: multi-centre phase II double-blind RCT
Intention-to-treat: yes, used LOCF (last observation carried forward)
Countries: USA, Korea
Participants Number randomised: N = 52 (VM202 low-dose n = 21; VM202 high-dose n = 20;
placebo n = 11)
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Losses to follow-up and withdrawals: VM202 low-dose n = 1, VM202 high-dose n =
2, placebo n = 1; 3/21 (14.3%) did not complete study in VM202 low-dose group, 3/
20 (15.0%) did not complete study in VM202 high-dose group, 3/11 (27.3%) did not
complete study in placebo group; 1 person from each group withdrew; 1 person in the
placebo group died, as did 1 person in the low-dose group
Age (mean years ± SD): VM202 low-dose 65.9 ± 10.7; VM202 high-dose 67.2 ± 10.
9; placebo 64.3 ± 14.5
Gender (M): VM202 low-dose 66.7%; VM202 high-dose 65.0%; placebo 54.5%
Inclusion criteria: 18 to 90 years old; CLI (Rutherford Class 4 to 5); deemed to be poor
or suboptimal candidates for bypass graft surgery or endovascular revascularisation; ≥ 1
hallmark symptom of CLI (ischaemic rest pain, focal gangrene (< 3 cm))
Exclusion criteria: pregnant women; successful revascularisation procedure or sympa-
thectomy within 12 weeks before study initiation; major amputation anticipated in the
target leg within 4 weeks of the start of treatment; estimated life expectancy < 6 months;
thromboangiitis obliterans; deep tissue ulcerations with bone or tendon exposure or
clinical evidence of invasive infection uncontrollable by antibiotics; required > 81 mg
per day aspirin; currently receiving immunosuppressive medications, COX-1/COX-2
inhibitor drugs, high-dose steroids, chemotherapy, or radiation; history within 5 years or
new finding of malignant neoplasm; New York Heart Association Class III or IV heart
failure; history of stroke or myocardial infarction within the last 6 months; unstable
angina or proliferative retinopathy; any of the following laboratory findings: positive
HIV, human T-lymphotrophic virus, hepatitis B or C
Interventions Treatment
VM202 (plasmid DNA expressing 2 isoforms of HGF) low-dose - 1 × 4 mg VM202
intramuscular injections, 16 total injections into the affected leg according to a schedule
that targeted the vascular compartments corresponding to occluded segments, given on
day 0 and again on day 14 (8 mg total), followed by saline on days 28 and 42
VM202 high-dose - 1 × 4 mg VM202, in the same manner as above, on day 0, and again
on days 14, 28, and 42 (16 mg total)
Control: placebo, saline, in the same manner as above, on days 0, 14, 28, and 42
Outcomes Follow-up times: days 14, 28, and 42, and 3, 6, 9, and 12 months
Outcomes: Adverse events, Difference in pain severity measured by VAS between base-
line and 9 months, Change in VAS, Ulcer healing, Skin perfusion by TcPO , ABI
and TBI, Rutherford Classification, Quality of life score using VascuQoL, Amputation,
Mortality during 12 months
Notes Study period: July 2010 to July 2012
NCT01064440
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to de-
termine random sequence generation; de-
scribed only as a “1:2:2 scheme to placebo,
low-dose or high-dose”
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Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how saline
placebo was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low risk of attrition bias, as all participants
accounted for; ITT analysis and LOCF per-
formed
Selective reporting (reporting bias) Low risk All outcomes listed in Methods reported on
Other bias Unclear risk Funding by ViroMed; 1 study author re-
ceives consulting fees from ViroMed but
specified that sole responsibility for data,
statistical analysis, and manuscript content
lies with the study authors - not the funders
Kusumanto 2006
Methods Study design: multi-centre double-blind placebo-controlled RCT
Intention-to-treat: not specified but all participants evaluated for all endpoints
Country: The Netherlands
Participants Number randomised: N = 54 (phVEGF165 n = 27; placebo n = 27)
Losses to follow-up and withdrawals: N = 0
Age (mean years (range)): phVEGF165 68.7 (45 to 85); control 68.4 (40 to 84)
Gender (M): phVEGF165 59.2%; control 55.6%
Inclusion criteria: type 1 or type 2 diabetes mellitus established according to current
American Diabetes Association criteria; evidence of CLI including rest pain and/or ulcers
that had not healed for a minimum of 2 weeks despite conventional therapy; compressible
vessels with resting ankle systolic blood pressure < 50 mmHg or toe systolic blood pressure
< 30 mmHg; unsuitable candidates for surgical or percutaneous revascularisation judged
after contrast angiography by vascular surgeon and intervention radiologist
Exclusion criteria: active proliferative diabetic retinopathy; history of malignancy; severe
comorbidity, compromising comedications
Interventions Treatment: phVEGF165, 2000 µg, on days 0 and 28, 4 aliquots, 500 µg each, diluted
in 1.0 mL NaCl, injected intramuscularly into the thigh and calf of the most ischaemic
limb; injection sites chosen arbitrarily according to available muscle mass
Control: placebo, on days 0 and 28
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Outcomes Follow-up times: days 7, 14, 35, 42, 72, and 100
Outcomes: Amputation, ABI, TBI, Skin improvements, Pain, QoL using RAND-36
questionnaire, Safety outcomes
Notes Study period: February 2000 to January 2004
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised block randomisation with-
out stratification or matching, performed
by the pharmacy of the University Medical
Center Groningen
Allocation concealment (selection bias) Unclear risk Not specified how allocation concealment
was carried out
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double-blind; “no difference
between the phVEGF165 and placebo
could be seen or felt by the physician who
performed the injection”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Supported by a grant from Fornix Bio-
Sciences
Makinen 2002
Methods Study design: phase II placebo-controlled double-blind RCT
Intention-to-treat: yes
Country: Finland
Participants Number randomised: N = 54 (VEGF-AdV n = 18; VEGF-P/L n = 17; control n = 19)
Losses to follow-up and withdrawals: at 3 months: VEGF-Ad n = 3; VEGF-P/L n =
1; control n = 2)
Age (mean years (range)): VEGF-AdV 70 (53 to 86); VEGF-P/L 74 (55 to 84); control
73 (61 to 86)
Gender (M): VEGF-AdV 50.0%; VEGF-P/L 35.3%; control 42.1%
Inclusion criteria: angiographically proven atherosclerotic infrainguinal stenosis or oc-
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clusion suitable for PTA
Exclusion criteria: type 1 diabetes; malignancy; osteomyelitis; fertile women age < 50
years; signs of active inflammation; abnormal prostate-specific antigen or carcinoembry-
onic antigen values; poor cooperation
Interventions Treatment:
2 × 10¹ pfu VEGF-AdV, intra-articular catheter administration following PTA
VEGF-P/L (2000 µg VEGF plasmid plus 2000 µL DOTMA:DOPE) intra-articular
catheter administration following PTA
Control: placebo, Ringer’s lactate, intra-articular catheter administration following PTA
Outcomes Follow-up times: 1 and 3 months, median follow-up 24 months for safety outcomes
Outcomes: Ischaemic status using Rutherford Classification, ABI, Vascular assessment,
Restenosis rate
Notes Study period: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation done before beginning of
study; block of 9 people; used a procedure
based on random digits
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Used control placebo treatment; “treat-
ment and follow up were made in double-
blinded manner”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Treatment and follow up were made in
double-blinded manner”; image analysis
was carried out by blinded assessors who
did not have access to follow-up laboratory
or clinical information
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for and dropouts
clearly explained
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Supported by a grant from Kuopio Uni-
versity Hospital, Ark Therapeutics Ltd.,
Boston Scientific Inc., and Valentis
42Gene therapy for peripheral arterial disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mohler 2003
Methods Study design: phase I double-blind placebo-controlled dose-escalating RCT
Intention-to-treat: not specified
Country: USA
Participants Number randomised with IC: n = 18 (CI-1023 n = 15 (4 × 10 n = 3, 4 × 10 .
n = 3, 4 × 10 n = 3, 4 × 10 . n = 3, 4 × 10¹ n = 3); placebo n = 3)
Number randomised with CLI: n = 15 (CI-1023 n = 13 (4 × 10 n = 3, 4 × 10 .
n = 3, 4 × 10 n = 3, 4 × 10 . n = 3, 4 × 10¹ n = 1); placebo n = 2)
Losses to follow-up and withdrawals with IC: n = 1 in CI-1023 lost to follow-up; n
= 5 withdrew (n = 3 in CI-1023; n = 2 in placebo)
Losses to follow-up and withdrawals with CLI: n = 5 (CI-1023 n = 5; placebo n = 1)
Age (mean years ± SD) with IC: not specified
Age (mean years ± SD) with CLI: 73 ± 8
Gender (M) with IC: 78%
Gender (M) with CLI: 67%
Inclusion criteria with IC: men or women > 40 years of age; patent inflow (aorto-iliac
segments); angiographic evidence of > 35% stenosis involving infrageniculate vessels
and disabling claudication; demonstrable ABI at rest < 0.90 and/or exercise ABI < 0.75
confirmed on 2 different occasions 2 days apart
Exclusion criteria with IC: advanced or unstable medical disease; renal insufficiency;
proliferative retinopathy; history of malignancy other than non-melanoma skin cancers
Inclusion criteria with CLI: atherosclerotic peripheral arterial disease (PAD); > 35 years
of age; patent inflow and angiographic evidence of infra-inguinal disease (> 50% stenosis)
involving the common femoral, superficial femoral, popliteal artery or infrapopliteal
vessels and ongoing rest pain or tissue loss (grades II and II of the Joint Council of
the Society for Vascular Surgery and the North American Chapter of the International
Society for Cardiovascular Surgery Classification comprising categories 4 and 5 with
demonstrable resting ABI < 0.70 and exercise ABI < 0.60 confirmed on 2 different
occasions 2 days apart)
Exclusion criteria with CLI: advanced renal or liver disease; evidence of infection of any
type, including adenovirus, hepatitis virus (A, B, or C), or HIV; ophthalmological exam
indicative of retinopathy; history of malignancy other than non-melanoma skin cancers;
successful surgical or endoluminal revascularisation of lower extremity to be treated;
unstable angina; coronary artery disease requiring immediate surgical or angioplasty in-
tervention, or recent transmural MI or CVA; serious CNS, psychiatric, musculoskeletal,
or immune disease
Interventions Treatment: CI-1023 (AdGVVEGF121.10), dose escalation from 4 × 10 to 4 × 10¹
particle units in half-log increments with 1 week between each dosage group for safety;
1-mL intramuscular injections into 20 sites of the ischaemic lower limb; anatomical
region of administration varied dependent on location of disease and vascular anatomy
Control: placebo diluent, in the same manner as treatment
Outcomes Follow-up times with IC: days 1, 7, 15, 30, 90, and 180 and 12 months
Outcomes with IC: Safety parameters, Walking ability using Gardner protocol, ABI,
Anti-adenovirus neutralising antibodies, Adenoviral cultures, VEGF levels
Follow-up times with CLI: 1 year
Outcomes with CLI: Safety parameters including gangrene and amputation, ABI
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Notes Study period: reported all 13 participants receiving CI-1023 as 1 group, although dif-
ferent doses were received based on dose-escalation schedule
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Insufficient information provided to de-
termine randomisation sequence; protocol
was altered due to participants’ refusal of
placebo over treatment, which could be ev-
idence of improper random sequence gen-
eration and allocation concealment; at each
week or dose, 3 participants were meant to
receive treatment and 1 placebo; this was
altered after 3 doses for above reasons
Allocation concealment (selection bias) High risk Insufficient information provided to deter-
mine randomisation sequence; protocol al-
tered due to participants’ refusal of placebo
over treatment, which could be evidence
of improper random sequence generation
and allocation concealment; at each week
or dose, 3 participants were meant to re-
ceive treatment and 1 placebo; this was al-
tered after 3 doses for above reasons
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how saline
placebo was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts of all participants reported, but
in CLI group, 5 of 15 participants with-
drew or were lost to follow-up (this left only
1 participant in the placebo arm), and 6
of 18 participants withdrew or were lost to
follow-up in the IC group
Selective reporting (reporting bias) Low risk All outcomes reported but no protocol
identified
Other bias High risk Very few numbers in this study and only
2 participants in the control group for the
CLI study; 3 for IC
Major change in protocol: after first 3 dos-
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ing cohorts, protocol was modified to an
open-label format with no placebo arm
because of refusal to participate due to
placebo arm - same for both IC and CLI
studies
Nikol 2008
Methods Study design: multi-centre phase II double-blind placebo-controlled RCT
Intention-to-treat: yes, modified intention-to-treat (MITT): those who (1) received at
least 2 treatment injections of a study drug, (2) had undergone an evaluation for aggregate
ulcer size at baseline and had at least 1 non-healing ulcer, and (3) had undergone an
evaluation for aggregate ulcer size at or after week 5; safety population included all those
who received at least 1 treatment injection
Countries: Belgium, France, Germany, Italy, Switzerland, UK
Participants Number randomised: N = 125 (NV1FGF n = 59; placebo n = 66); MITT N = 107
(NV1FGF n = 51; placebo n = 56)
Losses to follow-up and withdrawals: N = 18; rate of discontinuation NV1FGF 45.
5%; placebo 30.5%; discontinuation from adverse events NV1FGF n = 4; placebo n =
10
Age (mean years ± SD): NV1FGF 71.1 ± 10.4; placebo 73.3 ± 9.8
Gender (M): NV1FGF 64.7%; placebo 75%
Inclusion criteria: men and women aged ≥ 45 years, with CLI (defined according
to TASC, both arterial occlusion (angiography or doppler) and pressure (resting ankle
pressure ≤ 70 mmHg and/or toe pressure ≤ 50 mmHg, and or TcPO ≤ 20 mmHg and/
or metatarsal pulse volume recording barely pulsatile) who presented with non-healing
ulcers and for whom revascularisation was not considered a suitable option, with signs of
healing of trophic lesions absent for ≥ 2 weeks before first administration of study drug;
unsuitable for revascularisation for 1 or more of the following reasons: (1) poor or no
autologous graft material, (2) revascularisation would result in incomplete perfusion of
the foot, (3) high risk of failure for technical reasons, (4) safety risk associated with the
procedure, and (5) high risk of amputation on account of conditions such as gangrene
Exclusion criteria: previous or current history of malignant disease (patients who had
successful tumour resection or radiochemotherapy more than 5 years before inclusion
in the study and no recurrence allowed for inclusion); suspicion of malignant disease
(abnormal X-ray, positive stool haemoccult, positive prostate-specific antigen, abnormal
mammography, Papanicolaou smear of Class IV or Class V characterisation); lower
extremity surgery: bypass/angioplasty of the leg to be treated within 2 months before
first administration of study treatment (day 1); active PDR; Buerger’s disease
Interventions Treatment: 2.5 mL NV1FGF at 0.2 mg/mL, 8 intramuscular injections in a single
leg (if bilateral CLI, leg estimated to benefit the most based on lower haemodynamic
parameters), with 4 into the calf and 4 into the thigh, with sites selected based on muscle
mass, ulcer location, and distance from an artery or main nerve; injections given on days
1, 15, 30, and 45 for a total of 16 mg
Control: placebo, saline, given in the same manner as treatment
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Outcomes Follow-up times: weeks 13, 25, 38, and 52
Outcomes: Complete healing of at least 1 ulcer, ABI, Amputation, Death, Ischaemic
rest pain during previous 7 days (VAS), Safety (adverse events, physical exam, vital signs,
lab tests, ophthalmological exams, chest X-ray, mammography)
Notes Study period: enrolment April 2002 to April 2004
NCT00368797
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised in order enrolled via per-
muted-block randomisation in blocks of 4
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how placebo
was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Utilised a blinded review panel to recon-
cile discordance between investigators’ as-
sessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk All losses and discontinuations reported
Selective reporting (reporting bias) Low risk All outcomes from ClinicalTrials.gov pro-
tocol reported
Other bias Unclear risk Sponsored by Centelion SAS, a subsidiary
of Sanofi; sponsor collected data, moni-
tored the conduct of the study, and co-or-
dinated writing of the manuscript
Powell 2008
Methods Study design: multi-centre phase II double-blind placebo-controlled RCT
Intention-to-treat: not specified but last observation carried forward method used for
missing data; evaluated participants who received at least 1 dose n = 104 (low-dose n =
26; mid-dose n = 25; high-dose n = 27; placebo n = 26)
Country: USA
Participants Number randomised: N = 106 (low-dose AMG0001 n = 27; mid-dose AMG0001 n =
26; high-dose AMG0001 n = 27; placebo n = 26)
Losses to follow-up and withdrawals: reported N = 93 evaluated for safety
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Age (mean years): low-dose 70.1; mid-dose 73.0; high-dose 68.1; placebo 70.2
Gender (M): low-dose 76%; mid-dose 57%; high-dose 57%; placebo 63%
Inclusion criteria: age ≥ 40 years; 1 or more clinical indications diagnostic of CLI: distal
extremity pain at rest that requires the patient to use analgesics for > 2 weeks, or peripheral
ischaemic ulcers or areas of gangrene; TcPO < 40 mmHg; ankle systolic pressure <
70 mmHg or toe pressure < 50 mmHg; poor candidates for standard revascularisation
treatment on the basis of inadequate bypass conduit, unfavourable anatomy, or poor
operative risk
Exclusion criteria: people who, in the opinion of the investigator, had a vascular disease
prognosis that indicated they would require a major amputation within 4 weeks of the
start of treatment; diagnosis of Buerger’s disease (thromboangiitis obliterans); haemody-
namically significant aorto-iliac occlusive disease; deep ulcerations with bone or tendon
exposure or clinical evidence of invasive infection uncontrollable by antibiotics; receiv-
ing immunosuppressive medication, chemotherapy, or radiation; end-stage renal disease
and receiving long-term haemodialysis, with evidence of malignant neoplasm (except for
fully resolved basal cell carcinoma); PDR; severe non-proliferative retinopathy; recent
retinal vein occlusion; macular degeneration with choroidal neovascularisation; macular
oedema on fundus evaluation by ophthalmologist; intraocular surgery within 3 months
Interventions Treatment:
Low-dose AMG0001 - 0.4 mg at days 0, 14, and 28; intramuscular injections, 8 locations:
4 injections at lateral and medial locations in the anterior and posterior distal limb and
4 locations in the posterior calf of the affected limb
Mid-dose AMG0001 - 4.9 mg at days 0 and 28; saline placebo given on day 14, in the
same manner as above
High-dose AMG0001 - 4.0 mg at days 0, 14, and 28, in the same manner as above
Control: placebo, saline, at days 0, 14, and 28, in the same manner as above
Outcomes Follow-up times: weeks 1 to 5 and week 7, as well as months 3, 6, and 12
Outcomes: Safety (adverse events, concomitant medication use, ECG, blood chemistry,
haematology, coagulation, urinalysis, vital signs, physical exam, cancer and retinopathy
screening, assays for HGF plasmid, protein and antibodies), TcPO , ABI/TBI, Ampu-
tation and ulcer healing, Mortality, Pain (VAS), Rutherford Classification, QoL (SF-36)
Notes Study period: April 2003 to January 2007
NCT00060892
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine adequate random sequence genera-
tion; randomised to 4 groups at ratio 1:1:
1:1
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how placebo
was disguised for personnel




gov protocol describes quadruple blinding
that included the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported outcomes for all participants re-
ceiving at least 1 dose and provided data for
withdrawals
Selective reporting (reporting bias) Unclear risk No data provided on pain (VAS) or QoL
Other bias Unclear risk Funded by AnGes Inc.
Powell 2010
Methods Study design: multi-centre double-blind placebo-controlled RCT
Intention-to-treat: safety outcomes analysed by ITT, defined as all randomised par-
ticipants who received at least 1 dose of treatment; efficacy evaluable (EE) population
included all participants who received all 3 doses and had at least 1 follow-up visit after
receiving all 3 doses but before having a peripheral vascular intervention or major am-
putation
Country: USA
Participants Number randomised: N = 27 (AMG0001 n = 21; placebo n = 6)
Losses to follow-up and withdrawals: withdrawal by participant AMG0001 n = 3;
placebo n = 0
Age (mean years ± SD): 76.2 ± 1.97 (AMG0001 75.7 ± 2.49; placebo 78.0 ± 1.86)
Gender (M): 55.6% (AMG0001 61.9%; placebo 33.3%)
Inclusion criteria: appropriately sized ischaemic peripheral ulcer(s) or tissue loss (pho-
tographs of wounds reviewed by a vascular specialist before enrolment); 1 or both of
the following haemodynamic indicators of severe peripheral arterial occlusive disease:
ankle systolic pressure ≤ 70 mmHg or toe systolic pressure ≤ 50 mmHg, poor candidate
for standard revascularisation treatment options for peripheral arterial disease based on
inadequate bypass conduit, unfavourable anatomy, or poor operative risk
Exclusion criteria: patients who, in the opinion of the investigator, had a vascular disease
prognosis that indicated they may require a major amputation (at or above the ankle)
within 4 weeks of the start of treatment; diagnosis of Buerger’s disease (thromboangitis
obliterans); haemodynamically significant aorto-iliac occlusive disease; revascularisation
procedure within 12 weeks before treatment initiation that remained patent (revascular-
isation procedures evidenced to have failed (completely occluded) for > 2 weeks before
treatment initiation were acceptable); deep ulcerations with bone or tendon exposure,
or clinical evidence of invasive infection uncontrollable by antibiotics; evidence or his-
tory of malignant neoplasm (clinical, laboratory, or imaging), except for fully resolved
basal cell carcinoma of the skin (people who underwent successful tumour resection or
radiochemotherapy of breast cancer more than 10 years before inclusion in the study,
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and with no recurrence, could be enrolled, and who had successful tumour resection
or radiochemotherapy of all other tumour types more than 5 years before inclusion in
the study, and with no recurrence, could be enrolled in the study); proliferative dia-
betic retinopathy; severe nonproliferative retinopathy; recent (within 6 months) reti-
nal vein occlusion; macular degeneration with choroidal neovascularisation; macular
oedema on fundus evaluation by ophthalmologist; intraocular surgery within 3 months;
history of ESRD defined as significant by creatinine of 2.5 mg/dL, or receiving long-
term haemodialysis
Interventions Treatment: HGF plasmid AMG0001, 4.0 mg in 8 intramuscular injections, performed
under duplex ultrasound guidance in arteriographically chosen (by a central committee
of vascular specialists) locations for each participant based on regions of most severe
vascular disease; injection given at 3 time points 2 weeks apart (days 0, 14, and 28)
Control: placebo, given in the same manner as treatment
Outcomes Follow-up times: 3 months and 6 months
Outcomes: Adverse events, ABI and TBI, Rest pain (VAS), Wound healing (change in
size of ulcer), Amputation, Survival, QoL
Notes Study period: August 2005 to August 2008
NCT00189540
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine adequate random sequence genera-
tion; randomisation ratio was 4:1
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how placebo
was disguised for personnel




gov protocol describes quadruple blinding
that included the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Utilised ITT efficacy analysis; ClinicalTri-
als.gov report includes withdrawals
Selective reporting (reporting bias) Unclear risk QoL not reported
Other bias High risk Supported by AnGes Inc., for whom 2 of
the study authors are consultants
Sample size calculation estimated the
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need for N = 39 evaluable participants
(AMG0001 n = 26; placebo n = 13); ac-
tual evaluated numbers are far lower due to
early termination of the study
Reasons given for early termination: (1)
sufficient numbers to assess safety, (2)
demonstrated a signal of efficacy, and (3)
difficulty and slowness of recruitment
ClinicalTrials.gov report states that there
were “technical problems leading to unre-
liable or uninterpretable data”
Rajagopalan 2003
Methods Study design: multi-centre phase II double-blind placebo-controlled RCT
Intention-to-treat: yes, missing data analysed via last observation carried forward pro-
cedure
Country: USA
Participants Number randomised: N = 105 (low-dose AdVEGF121 n = 32; high-dose AdVEGF121
n = 40; placebo n = 33)
Losses to follow-up and withdrawals: N = 18 (low dose AdVEGF121 n = 9; high-dose
AdVEGF121 n = 2; placebo n = 8)
Age (mean years ± SD): low-dose AdVEGF121 66 ± 9; high-dose AdVEGF121 64 ±
9; placebo 68 ± 10
Gender (M): low-dose AdVEGF121 81%; high-dose AdVEGF121 68%; placebo 91%
Inclusion criteria: male and female; 40 to 80 years of age, with PAD (resting ABI < 0.80
in affected limb) and chronic, stable, predominantly unilateral intermittent claudication
≥ 6 months on a stable medication regimen, with exercise-associated flow limitation (>
20% fall in ABI with exercise) and unilateral exercise-limiting claudication, with exercise
duration between 1 and 10 minutes (and variability within 20%) on 2 consecutive graded
Gardner-Skinner protocols
Exclusion criteria: significant contralateral lower extremity symptoms and signs
Interventions Treatment:
Low-dose AdVEGF121 4 × 10 particle units - 20 1.0-mL intramuscular injections into
the index leg in a single session both anterior and posteriorly into the lower thigh or into
the lower thigh and the upper calf
High-dose AdVEGF121 4 × 10¹ particle units, given in the same manner as above
Control: vehicle alone, given in the same manner as above
Outcomes Follow-up times: 12 weeks and 26 weeks
Outcomes: PWT (graded Gardner-Skinner protocol), ABPI, COT, QoL (using SF-36
and WIQ), Safety (adverse event monitoring, physical exam, lab tests, resting ECGs,
ophthalmological exams, and cancer screens)
Notes Study period: not specified
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine adequate random sequence genera-
tion; stratified on the basis of diabetic sta-
tus
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and used
placebo but did not describe how placebo
was disguised for personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Utilised ITT analysis and clearly stated
numbers and reasons for loss to follow-up
Selective reporting (reporting bias) Low risk All outcomes from trial design paper re-
ported
Other bias Unclear risk Funded by GenVec; several study authors
are employees of or own stock in GenVec
Sample size calculation estimated for 35
people in each treatment group to provide
80% power to detect a mean difference of
1.5 minutes in change in PWT
Rajagopalan 2007
Methods Study design: multi-centre double-blind placebo-controlled; 2 trial phases: first phase
conducted as an RCT with n = 28 participants; second open-label phase with n = 10
participants added in the treatment group and n = 3 original placebo-treated participants
rolled over to receive gene therapy
Intention-to-treat: no, all participants receiving ≥ 1 HIF-1α or placebo injection were
included in the safety analysis
Country: USA
Participants Number randomised: N = 38 (HIF-1α n = 31; placebo n = 7)
Losses to follow-up and withdrawals: not reported
Age (mean years (range)): 66 (39 to 87) (HIF-1α 66 (39 to 87); placebo 67 (46 to 80)
)
Gender (M): 66% (HIF-1α 62%; placebo 100%)
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Inclusion criteria: between 21 and 45 years of age; no options for surgical or endovas-
cular revascularisation and total or subtotal occlusion of at least 1 main artery in a limb
confirmed by angiography; CLI (defined as Rutherford Category 4 or 5 present for a
minimum of 4 weeks without response to conventional therapies with lack of further
revascularisation options confirmed by both the investigator and an independent re-
viewer)
Exclusion criteria: contraindications to growth factor therapy that have been published
previously; inflammatory arthritis; Rutherford Category 6 status; prior successful lower
extremity arterial surgery, angioplasty, or lumbar sympathectomy during the 2 months
before screening; participated in other experimental protocols within 30 days of enrol-
ment or had ever been enrolled in a similar vascular endothelial growth factor or fibrob-
last growth factor adenoviral or plasmid gene therapy protocol
Interventions Treatment: Ad2/HIF-1α /VP16 - 1 × 10 to 1 × 10¹ viral particles (5 different treat-
ment groups), 10 × 100 µL intramuscular injections for a total volume of 1.0 mL,
into a single limb, placement of injections at discretion of investigator based on patient
anatomy and location of occluded artery or arteries
Control: placebo, phosphate-buffered saline with 10% sucrose, given in the same manner
as treatment
Outcomes Follow-up times: days 3, 7, 14, 21, 30, 45, 60, and 90, 6 months, and 1 year
Outcomes: Adverse events, Changes in baseline physical examinations, Clinical labora-
tory evaluations, Adenoviral antibody titre measurement, Retinal eye examinations and
examinations to assess rest pain, Healing of ischaemic ulcers, Rutherford Category, ABI,
MRA to detect vascular changes
Notes Study period: October 1999 to June 2004
Study reported pooled HIF-1α results and not per dosage; we are reporting HIF-1α as
a single treatment group
Treatment numbers reported in this review (HIF-1α n = 31) differ from the report, as
their n = 34 treated includes 3 participants originally randomised to placebo who were
rolled over, so are counted twice (in the control group as well)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided to deter-
mine random sequence generation
Allocation concealment (selection bias) Unclear risk Insufficient information provided to deter-
mine allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk First part of study was double-blind, but
second phase was open-label, where several
participants originally assigned to placebo
were rolled over to treatment; blinding
methods not described
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information provided only as total trial, not
separately by trial phases; withdrawals re-
ported in Figures 2 and 3 but only for those
with rest pain or ulcers
Selective reporting (reporting bias) Low risk All outcomes reported but ABI reportedly
not available for all study participants
Other bias High risk Study sponsored by Genzyme Corp., man-
ufacturer of Ad2/HIF-1α/VP16
Study incorporated a randomised, dou-
ble-blind, placebo-controlled first phase of
the study with an open-label phase af-
ter, where several placebo participants were
rolled over to treatment and therefore were
counted twice in the analysis
Shigematsu 2010
Methods Study design: multi-centre double-blind placebo-controlled RCT
Intention-to-treat: no, interim analysis carried out when participants reached N = 40
(HGF n = 27; placebo n = 13), and safety analysis N = 41 (HGF n = 28; placebo n = 13)
Country: Japan
Participants Number randomised: N = 46 (HGF n = 30; placebo n = 16)
Losses to follow-up and withdrawals: N = 6 (HGF n = 3; placebo n = 3)
Age (mean years ± SD): HGF 71.9 ± 7.6; placebo 72.8 ± 7.3
Gender (M): HGF 77.8%; placebo 53.8%
Inclusion criteria: all eligible participants screened by an eligibility committee composed
of vascular surgeons: aged 40 to 84 years with chronic CLI and rest pain or non-healing
ischaemic ulcers (Rutherford 4/Fontaine III or Rutherfor 5/Fontaine IV) persisting for
a minimum of 4 weeks; resting ABI < 0.6 and mean ankle blood pressure < 70 mmHg
in the affected limb according to 3 consecutive measurements performed at weeks -
4, -2, and 0, or TBI < 0.5 if ABI not measurable; ineligible for standard surgical or
percutaneous revascularisation and showed no response to conventional drug therapy
for at least 4 weeks
Exclusion criteria: deep ulcers that exposed bone or tendon; clinical evidence of invasive
infection uncontrolled by antibiotics; serious cardiac, hepatic, renal, or haematological
disease; current evidence or history of malignancy; PDR; neovascular age-related macular
degeneration; sympathectomy or sympathetic block within 6 months; revascularisation
or major amputation within 3 months
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Interventions Treatment: naked plasmid encoding human HGF gene (beperminogene perplasmid,
Collategene) - 0.5 mg of HGF plasmid in 3 mL saline given by 8 intramuscular injections
into the calf muscles and/or the distal thigh of the ischaemic limb under ultrasound
guidance; injection schedule repeated after 28 days
Control: placebo, saline, given in the same method as HGF plasmid
Outcomes Follow-up times: 12 and 24 weeks and 9 and 15 months
Outcomes: Improvement in rest pain (reduction in VAS scale > 20 mm compared with
baseline) in patients without ulcers or reduction in ulcer size (> 25% (approximately
50% change in area)) in patients with ulcers, ABI, Amputation, QoL using SF-36,
Safety (adverse events, concomitant medications, ECG, lab blood and urine tests, vital
signs, physical findings, cancer and retinopathy screenings, assays for HGF protein and
antibodies, Escherichia coli protein antibodies and DNA antibodies)
Notes Study period: pre-screened February 2004 to June 2007
After 12 weeks, participants were unblinded; those who received placebo could choose
to enter the next stage and receive active drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a modified minimisation method,
allocated by the central registration cen-
tre; randomisation ratio for plasmid-to-
placebo was 2:1
Allocation concealment (selection bias) Low risk Allocated by the central registration centre
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind, used placebo,
and described administration as given in
a blinded manner; at the time the study
reached N = 40, trial was terminated and
information about allocation of treatment
was opened to investigators; 3 patients had
not been evaluated and were excluded from
the analysis; 8 weeks after second adminis-
tration (12 weeks from first treatment), the
study treatment code was opened for each
participant, who could then receive HGF if
previously receiving placebo, if they wished
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to deter-
mine blinding of outcome assessment
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals and losses clearly presented in
the figure; due to trial terminated early and
unblinded, n = 3 were not yet evaluated and
were excluded from the final analysis
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk Funded and designed by AnGes MG, Inc.
(Osaka, Japan); formal data analysis per-
formed by a contract research organisation
Study power calculation required for n = 80
in the HGF plasmid group and n = 40 in
the placebo group, but with slow recruit-
ment, the analysis was changed to an in-
terim analysis with total N = 40, with only
n = 13 in the placebo group
ABI: ankle brachial pressure index.
CLI: critical limb ischaemia.
CNS: central nervous system.
COT: claudication onset time.
CT: computerised tomography.
CVA: cerebrovascular accident.





ESRD: end-stage renal disease.
EuroQol: quality of life tool.
FGF: fibroblast growth factor.
HGF: hepatocyte growth factor.
HIF-1α: hypoxia-inducible factor 1-alpha.
HIV: human immunodeficiency virus.
IC: intermittent claudication.
ITT: intention-to-treat.





mmHg: millimetre of mercury.
MRA: magnetic resonance angiography.
NaCl: sodium chloride.
NV1FGF: non-viral 1 FGF.
PAD: peripheral arterial disease.
PDR: proliferative diabetic retinopathy.
Pfu: plaque forming unit.
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PTA: percutaneous transluminal angioplasty.
PWD: pain-free walking distance.
PWT: peak walking time.
QoL: quality of life.
RAND-36: quality of life tool.
RCT: randomised controlled trial.
SD: standard deviation.
SDF-1: stromal cell-derived factor-1.
SF-36: Short Form-36; quality of life tool.
TASC: Trans-Atlantic Inter-Society Consensus.
TBI: toe brachial pressure index.
TcPO : transcutaneous oximetry.
VascuQoL: vascular quality of life questionnaire.
VAS: visual analogue scale.
VEGF: vascular endothelial growth factor.
VEGF-AdV: VEGF-adenovirus.
VEGF-P/L: VEGF-plasmid/liposome.
WIQ: Walking Impairment Questionnaire; quality of life tool.
µg: microgram.
µL: microlitre.
TcPO : transcutaneous oximetry.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anghel 2011 Not a randomised study
Biggs 2009 No use of a control comparator group and insufficient diagnostic criteria for PAD
de Leeuw 2008 Insufficient follow-up period (28 days)
Gavrilenko 2008 Insufficient diagnostic criteria for PAD; unclear if treatment fits inclusion criteria
Gavrilenko 2015 Only partially randomised and insufficient diagnostic criteria for PAD
Kalka 2000 Insufficient diagnostic criteria for PAD
Korpisalo 2015 Insufficient diagnostic criteria for PAD; unclear if this is a randomised study
Kusumanto 2001 Insufficient diagnostic criteria for PAD; unclear if this is a randomised study
Laitinen 1998 Insufficient diagnostic criteria for PAD; unclear if this is a randomised study
Makinen 1999 Insufficient diagnostic criteria for PAD
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Morishita 2014 Insufficient diagnostic criteria for PAD; unclear if this is a randomised study
NCT02016755 Not a randomised study
NCT02544204 Insufficient diagnostic criteria for PAD
Powell 2003 Insufficient diagnostic criteria for PAD
Rauh 1999 Insufficient diagnostic criteria for PAD
Talitskiy 2012 Insufficient diagnostic criteria for PAD
PAD: peripheral arterial disease.
Characteristics of ongoing studies [ordered by study ID]
Fujino 2013
Trial name or title The efficacy and safety of DVC1-0101 for intermittent claudication secondary to peripheral artery disease:
study protocol of a randomised phase IIb trial
Methods Phase IIb randomised placebo-controlled parallel-design single-dose blinded single-centre clinical trial in
Japan
Participants Plan to enrol 60 participants with diagnosis of PAD with intermittent claudication
Interventions DVC1-0101 (low dose or high dose) or placebo administered by direct intramuscular injection
Outcomes Peak walking time, Safety and tolerability, Claudication onset time, Quality of life measured by the Walking
Impairment Questionnaire, Qualifying limb haemodynamics, Pharmacodynamics of DVC1-0101 by evalu-
ating biomarkers
Starting date March 2014
Contact information Michiko Tanaka; tmiciko@med.kyushu-u.ac.jp
Notes
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Trial name or title EW-A-401 to treat intermittent claudication
Methods Randomised double-blind dose-escalation placebo-controlled study
Participants Participants with intermittent claudication
Interventions EW-A-401 or placebo
Outcomes Safety and toxicity, Blood flow, Walking capacity, Quality of life, Inspection of blood vessels
Starting date March 2004
Contact information National Institutes of Health Clinical Center (CC)
Notes
NCT00304837
Trial name or title VEGF gene transfer for critical limb ischemia
Methods Randomised cross-over double-blind clinical trial
Participants Moderate- to high-risk critical limb ischaemia
Interventions pVGI.1 (VEGF-2) or placebo
Outcomes Rest pain, Ulcer healing
Starting date March 2006
Contact information Douglas Losordo
Notes Completed in April 2008
NCT02144610
Trial name or title Efficacy and safety of AMG0001 in subjects with critical limb ischemia (AGILITY)
Methods Phase III randomised parallel-assignment quadruple-blinded placebo-controlled study
Participants Participants with critical limb ischaemia
Interventions HGF plasmid (AMG0001) or placebo
Outcomes Time to major amputation, Major amputation and revascularisation, Complete ulcer healing, Ischaemic rest
pain, Quality of life, Incident stroke and myocardial infarction, Primary bypass graft patency
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Starting date May 2014
Contact information Richard J Powell; Dartmouth-Hitchcock Medical Center
Notes
HGF: hepatocyte growth factor.
PAD: peripheral arterial disease.
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D A T A A N D A N A L Y S E S
Comparison 1. Gene therapy versus no gene therapy control




participants Statistical method Effect size
1 Amputation-free survival 4 756 Odds Ratio (M-H, Random, 95% CI) 1.68 [0.75, 3.76]
2 Complete ulcer healing 5 238 Odds Ratio (M-H, Fixed, 95% CI) 2.16 [1.02, 4.59]
3 Amputation (above-ankle
amputation of the index limb)
11 1336 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.77, 1.46]
4 All-cause mortality 12 1685 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.66, 1.31]
5 ABI - change from baseline 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Pain symptom scores (VAS) 2 152 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.83, 0.38]
Comparison 2. Subgroup by PAD classification: gene therapy versus no gene therapy control




participants Statistical method Effect size
1 Amputation (above-ankle
amputation of the index limb)
11 1336 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.77, 1.46]
1.1 Intermittent claudication 1 105 Odds Ratio (M-H, Fixed, 95% CI) 0.45 [0.03, 7.43]
1.2 Critial limb ischaemia 9 1131 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.78, 1.50]
1.3 Intermittent claudication
and critical limb ischaemia
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.15, 4.52]
2 All-cause mortality 12 1685 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.66, 1.31]
2.1 Intermittent claudication 2 394 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.27, 1.73]
2.2 Critical limb ischaemia 9 1191 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
2.3 Intermittent claudication
and critical limb ischaemia
1 100 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [0.19, 15.42]
Comparison 3. Subgroup by dosage schedule: gene therapy versus no gene therapy control




participants Statistical method Effect size
1 Amputation (above-ankle
amputation of the index limb)
11 1336 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.77, 1.46]
1.1 Single dosage schedule 5 453 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [0.53, 4.98]
1.2 Repeat dosage schedule 6 883 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.73, 1.42]
2 Complete ulcer healing 5 238 Odds Ratio (M-H, Fixed, 95% CI) 2.16 [1.02, 4.59]
2.1 Single dosage schedule 2 37 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.21, 7.47]
2.2 Repeat dosage schedule 3 201 Odds Ratio (M-H, Fixed, 95% CI) 2.43 [1.06, 5.56]
3 All-cause mortality 12 1685 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.66, 1.31]
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3.1 Single dosage schedule 5 696 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.31, 1.30]
3.2 Repeat dosage schedule 7 989 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.70, 1.52]
Comparison 4. Subgroup by vector type: gene therapy versus no gene therapy control




participants Statistical method Effect size
1 Amputation (above-ankle
amputation of the index limb)
11 1336 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.77, 1.46]
1.1 Plasmid vector 9 1166 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.74, 1.42]
1.2 Viral vector 3 170 Odds Ratio (M-H, Fixed, 95% CI) 2.05 [0.43, 9.82]
2 All-cause mortality 12 1685 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.66, 1.30]
2.1 Plasmid vector 9 1226 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.69, 1.45]
2.2 Viral vector 4 459 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.29, 1.43]
Comparison 5. Subgroup by encoding gene: gene therapy versus no gene therapy control




participants Statistical method Effect size
1 Amputation-free survival 4 756 Odds Ratio (M-H, Random, 95% CI) 1.68 [0.75, 3.76]
1.1 FGF encoding 2 650 Odds Ratio (M-H, Random, 95% CI) 1.34 [0.46, 3.91]
1.2 VEGF encoding 1 54 Odds Ratio (M-H, Random, 95% CI) 3.95 [1.07, 14.65]
1.3 HGF encoding 1 52 Odds Ratio (M-H, Random, 95% CI) 1.56 [0.38, 6.38]
2 Complete ulcer healing 5 238 Odds Ratio (M-H, Fixed, 95% CI) 2.16 [1.02, 4.59]
2.1 FGF encoding 1 125 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.54, 4.04]
2.2 HGF encoding 3 92 Odds Ratio (M-H, Fixed, 95% CI) 5.06 [1.23, 20.84]
2.3 HIF-1α encoding 1 21 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.04, 8.05]
3 Amputation (above-ankle
amputation of the index limb)
11 1336 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.77, 1.46]
3.1 FGF encoding 2 650 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.75, 1.55]
3.2 HGF encoding 3 125 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.27, 4.81]
3.3 VEGF encoding 5 523 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.33, 1.69]
3.4 HIF-1α encoding 1 38 Odds Ratio (M-H, Fixed, 95% CI) 6.33 [0.33, 122.40]
4 All-cause mortality 12 1685 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.66, 1.31]
4.1 FGF encoding 2 650 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.69, 1.60]
4.2 HGF encoding 3 185 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.22, 2.50]
4.3 VEGF encoding 5 523 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.32, 2.09]
4.4 HIF-1α encoding 2 327 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.28, 1.63]
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Analysis 1.1. Comparison 1 Gene therapy versus no gene therapy control, Outcome 1 Amputation-free
survival.
Review: Gene therapy for peripheral arterial disease
Comparison: 1 Gene therapy versus no gene therapy control
Outcome: 1 Amputation-free survival








Belch 2011 163/259 180/266 34.9 % 0.81 [ 0.57, 1.16 ]
Kibbe 2016 30/41 7/11 17.5 % 1.56 [ 0.38, 6.38 ]
Kusumanto 2006 23/27 16/27 18.8 % 3.95 [ 1.07, 14.65 ]
Nikol 2008 37/59 27/66 28.8 % 2.43 [ 1.18, 4.99 ]
Total (95% CI) 386 370 100.0 % 1.68 [ 0.75, 3.76 ]
Total events: 253 (Gene therapy), 230 (Control)
Heterogeneity: Tau2 = 0.45; Chi2 = 11.29, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Control Favours Gene therapy
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Analysis 1.2. Comparison 1 Gene therapy versus no gene therapy control, Outcome 2 Complete ulcer
healing.
Review: Gene therapy for peripheral arterial disease
Comparison: 1 Gene therapy versus no gene therapy control
Outcome: 2 Complete ulcer healing
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kibbe 2016 22/40 1/9 7.5 % 9.78 [ 1.12, 85.65 ]
Nikol 2008 10/59 8/66 63.9 % 1.48 [ 0.54, 4.04 ]
Powell 2010 4/21 0/6 6.1 % 3.34 [ 0.16, 71.10 ]
Rajagopalan 2007 4/18 1/3 13.6 % 0.57 [ 0.04, 8.05 ]
Shigematsu 2010 4/11 1/5 8.9 % 2.29 [ 0.19, 28.19 ]
Total (95% CI) 149 89 100.0 % 2.16 [ 1.02, 4.59 ]
Total events: 44 (Gene therapy), 11 (Control)
Heterogeneity: Chi2 = 3.46, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Gene therapy versus no gene therapy control, Outcome 3 Amputation (above-
ankle amputation of the index limb).
Review: Gene therapy for peripheral arterial disease
Comparison: 1 Gene therapy versus no gene therapy control
Outcome: 3 Amputation (above-ankle amputation of the index limb)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belch 2011 67/259 55/266 55.3 % 1.34 [ 0.89, 2.01 ]
Deev 2015 5/75 2/25 3.9 % 0.82 [ 0.15, 4.52 ]
Deev 2017 6/150 2/60 3.8 % 1.21 [ 0.24, 6.16 ]
Kibbe 2016 6/41 1/11 1.9 % 1.71 [ 0.18, 15.95 ]
Kusumanto 2006 3/27 6/27 7.3 % 0.44 [ 0.10, 1.97 ]
Makinen 2002 1/35 0/19 0.8 % 1.70 [ 0.07, 43.66 ]
Nikol 2008 8/59 19/66 21.3 % 0.39 [ 0.16, 0.97 ]
Powell 2010 6/21 2/6 3.1 % 0.80 [ 0.11, 5.59 ]
Rajagopalan 2003 1/72 1/33 1.9 % 0.45 [ 0.03, 7.43 ]
Rajagopalan 2007 9/31 0/7 0.8 % 6.33 [ 0.33, 122.40 ]
Shigematsu 2010 0/30 0/16 Not estimable
Total (95% CI) 800 536 100.0 % 1.06 [ 0.77, 1.46 ]
Total events: 112 (Gene therapy), 88 (Control)
Heterogeneity: Chi2 = 9.42, df = 9 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Gene therapy versus no gene therapy control, Outcome 4 All-cause mortality.
Review: Gene therapy for peripheral arterial disease
Comparison: 1 Gene therapy versus no gene therapy control
Outcome: 4 All-cause mortality
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belch 2011 46/259 39/266 46.0 % 1.26 [ 0.79, 2.00 ]
Creager 2011 14/213 6/76 12.0 % 0.82 [ 0.30, 2.22 ]
Deev 2015 5/75 1/25 2.0 % 1.71 [ 0.19, 15.42 ]
Deev 2017 3/150 2/60 4.1 % 0.59 [ 0.10, 3.63 ]
Kibbe 2016 1/41 1/11 2.2 % 0.25 [ 0.01, 4.35 ]
Kusumanto 2006 2/27 2/27 2.7 % 1.00 [ 0.13, 7.67 ]
Makinen 2002 2/35 1/19 1.8 % 1.09 [ 0.09, 12.87 ]
Nikol 2008 6/59 13/66 16.0 % 0.46 [ 0.16, 1.31 ]
Powell 2008 5/80 2/26 4.1 % 0.80 [ 0.15, 4.39 ]
Powell 2010 4/21 1/6 1.8 % 1.18 [ 0.11, 13.07 ]
Rajagopalan 2003 0/72 1/33 3.0 % 0.15 [ 0.01, 3.77 ]
Rajagopalan 2007 3/31 2/7 4.3 % 0.27 [ 0.04, 2.03 ]
Total (95% CI) 1063 622 100.0 % 0.93 [ 0.66, 1.31 ]
Total events: 91 (Gene therapy), 71 (Control)
Heterogeneity: Chi2 = 7.53, df = 11 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Gene therapy versus no gene therapy control, Outcome 5 ABI - change from
baseline.
Review: Gene therapy for peripheral arterial disease
Comparison: 1 Gene therapy versus no gene therapy control
Outcome: 5 ABI - change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nikol 2008 59 0.05 (0.31) 66 0.01 (0.32) 0.04 [ -0.07, 0.15 ]
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Analysis 1.6. Comparison 1 Gene therapy versus no gene therapy control, Outcome 6 Pain symptom scores
(VAS).
Review: Gene therapy for peripheral arterial disease
Comparison: 1 Gene therapy versus no gene therapy control
Outcome: 6 Pain symptom scores (VAS)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nikol 2008 59 -0.22 (1.7306) 66 -0.1 (1.8182) 94.5 % -0.12 [ -0.74, 0.50 ]
Powell 2010 21 -1.9 (5.96) 6 0.06 (0.49) 5.5 % -1.96 [ -4.54, 0.62 ]
Total (95% CI) 80 72 100.0 % -0.22 [ -0.83, 0.38 ]
Heterogeneity: Chi2 = 1.85, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Subgroup by PAD classification: gene therapy versus no gene therapy control,
Outcome 1 Amputation (above-ankle amputation of the index limb).
Review: Gene therapy for peripheral arterial disease
Comparison: 2 Subgroup by PAD classification: gene therapy versus no gene therapy control
Outcome: 1 Amputation (above-ankle amputation of the index limb)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intermittent claudication
Rajagopalan 2003 1/72 1/33 1.9 % 0.45 [ 0.03, 7.43 ]
Subtotal (95% CI) 72 33 1.9 % 0.45 [ 0.03, 7.43 ]
Total events: 1 (Gene therapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Critial limb ischaemia
Belch 2011 67/259 55/266 55.3 % 1.34 [ 0.89, 2.01 ]
Deev 2017 6/150 2/60 3.8 % 1.21 [ 0.24, 6.16 ]
Kibbe 2016 6/41 1/11 1.9 % 1.71 [ 0.18, 15.95 ]
Kusumanto 2006 3/27 6/27 7.3 % 0.44 [ 0.10, 1.97 ]
Makinen 2002 1/35 0/19 0.8 % 1.70 [ 0.07, 43.66 ]
Nikol 2008 8/59 19/66 21.3 % 0.39 [ 0.16, 0.97 ]
Powell 2010 6/21 2/6 3.1 % 0.80 [ 0.11, 5.59 ]
Rajagopalan 2007 9/31 0/7 0.8 % 6.33 [ 0.33, 122.40 ]
Shigematsu 2010 0/30 0/16 Not estimable
Subtotal (95% CI) 653 478 94.3 % 1.08 [ 0.78, 1.50 ]
Total events: 106 (Gene therapy), 85 (Control)
Heterogeneity: Chi2 = 8.97, df = 7 (P = 0.25); I2 =22%
Test for overall effect: Z = 0.47 (P = 0.64)
3 Intermittent claudication and critical limb ischaemia
Deev 2015 5/75 2/25 3.9 % 0.82 [ 0.15, 4.52 ]
Subtotal (95% CI) 75 25 3.9 % 0.82 [ 0.15, 4.52 ]
Total events: 5 (Gene therapy), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 800 536 100.0 % 1.06 [ 0.77, 1.46 ]
Total events: 112 (Gene therapy), 88 (Control)
Heterogeneity: Chi2 = 9.42, df = 9 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.46, df = 2 (P = 0.79), I2 =0.0%
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Analysis 2.2. Comparison 2 Subgroup by PAD classification: gene therapy versus no gene therapy control,
Outcome 2 All-cause mortality.
Review: Gene therapy for peripheral arterial disease
Comparison: 2 Subgroup by PAD classification: gene therapy versus no gene therapy control
Outcome: 2 All-cause mortality
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intermittent claudication
Creager 2011 14/213 6/76 12.0 % 0.82 [ 0.30, 2.22 ]
Rajagopalan 2003 0/72 1/33 3.0 % 0.15 [ 0.01, 3.77 ]
Subtotal (95% CI) 285 109 15.0 % 0.69 [ 0.27, 1.73 ]
Total events: 14 (Gene therapy), 7 (Control)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
2 Critical limb ischaemia
Belch 2011 46/259 39/266 46.0 % 1.26 [ 0.79, 2.00 ]
Deev 2017 3/150 2/60 4.1 % 0.59 [ 0.10, 3.63 ]
Kibbe 2016 1/41 1/11 2.2 % 0.25 [ 0.01, 4.35 ]
Kusumanto 2006 2/27 2/27 2.7 % 1.00 [ 0.13, 7.67 ]
Makinen 2002 2/35 1/19 1.8 % 1.09 [ 0.09, 12.87 ]
Nikol 2008 6/59 13/66 16.0 % 0.46 [ 0.16, 1.31 ]
Powell 2008 5/80 2/26 4.1 % 0.80 [ 0.15, 4.39 ]
Powell 2010 4/21 1/6 1.8 % 1.18 [ 0.11, 13.07 ]
Rajagopalan 2007 3/31 2/7 4.3 % 0.27 [ 0.04, 2.03 ]
Subtotal (95% CI) 703 488 83.0 % 0.96 [ 0.66, 1.39 ]
Total events: 72 (Gene therapy), 63 (Control)
Heterogeneity: Chi2 = 5.92, df = 8 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
3 Intermittent claudication and critical limb ischaemia
Deev 2015 5/75 1/25 2.0 % 1.71 [ 0.19, 15.42 ]
Subtotal (95% CI) 75 25 2.0 % 1.71 [ 0.19, 15.42 ]
Total events: 5 (Gene therapy), 1 (Control)
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(. . . Continued)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 1063 622 100.0 % 0.93 [ 0.66, 1.31 ]
Total events: 91 (Gene therapy), 71 (Control)
Heterogeneity: Chi2 = 7.53, df = 11 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 0.73, df = 2 (P = 0.69), I2 =0.0%
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Analysis 3.1. Comparison 3 Subgroup by dosage schedule: gene therapy versus no gene therapy control,
Outcome 1 Amputation (above-ankle amputation of the index limb).
Review: Gene therapy for peripheral arterial disease
Comparison: 3 Subgroup by dosage schedule: gene therapy versus no gene therapy control
Outcome: 1 Amputation (above-ankle amputation of the index limb)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single dosage schedule
Deev 2017 6/150 2/60 3.8 % 1.21 [ 0.24, 6.16 ]
Makinen 2002 1/35 0/19 0.8 % 1.70 [ 0.07, 43.66 ]
Rajagopalan 2003 1/72 1/33 1.9 % 0.45 [ 0.03, 7.43 ]
Rajagopalan 2007 9/31 0/7 0.8 % 6.33 [ 0.33, 122.40 ]
Shigematsu 2010 0/30 0/16 Not estimable
Subtotal (95% CI) 318 135 7.3 % 1.62 [ 0.53, 4.98 ]
Total events: 17 (Gene therapy), 3 (Control)
Heterogeneity: Chi2 = 1.74, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Repeat dosage schedule
Belch 2011 67/259 55/266 55.3 % 1.34 [ 0.89, 2.01 ]
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(. . . Continued)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Deev 2015 5/75 2/25 3.9 % 0.82 [ 0.15, 4.52 ]
Kibbe 2016 6/41 1/11 1.9 % 1.71 [ 0.18, 15.95 ]
Kusumanto 2006 3/27 6/27 7.3 % 0.44 [ 0.10, 1.97 ]
Nikol 2008 8/59 19/66 21.3 % 0.39 [ 0.16, 0.97 ]
Powell 2010 6/21 2/6 3.1 % 0.80 [ 0.11, 5.59 ]
Subtotal (95% CI) 482 401 92.7 % 1.02 [ 0.73, 1.42 ]
Total events: 95 (Gene therapy), 85 (Control)
Heterogeneity: Chi2 = 7.54, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 800 536 100.0 % 1.06 [ 0.77, 1.46 ]
Total events: 112 (Gene therapy), 88 (Control)
Heterogeneity: Chi2 = 9.42, df = 9 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
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Analysis 3.2. Comparison 3 Subgroup by dosage schedule: gene therapy versus no gene therapy control,
Outcome 2 Complete ulcer healing.
Review: Gene therapy for peripheral arterial disease
Comparison: 3 Subgroup by dosage schedule: gene therapy versus no gene therapy control
Outcome: 2 Complete ulcer healing
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single dosage schedule
Rajagopalan 2007 4/18 1/3 13.6 % 0.57 [ 0.04, 8.05 ]
Shigematsu 2010 4/11 1/5 8.9 % 2.29 [ 0.19, 28.19 ]
Subtotal (95% CI) 29 8 22.5 % 1.25 [ 0.21, 7.47 ]
Total events: 8 (Gene therapy), 2 (Control)
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
2 Repeat dosage schedule
Kibbe 2016 22/40 1/9 7.5 % 9.78 [ 1.12, 85.65 ]
Nikol 2008 10/59 8/66 63.9 % 1.48 [ 0.54, 4.04 ]
Powell 2010 4/21 0/6 6.1 % 3.34 [ 0.16, 71.10 ]
Subtotal (95% CI) 120 81 77.5 % 2.43 [ 1.06, 5.56 ]
Total events: 36 (Gene therapy), 9 (Control)
Heterogeneity: Chi2 = 2.56, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.10 (P = 0.036)
Total (95% CI) 149 89 100.0 % 2.16 [ 1.02, 4.59 ]
Total events: 44 (Gene therapy), 11 (Control)
Heterogeneity: Chi2 = 3.46, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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Analysis 3.3. Comparison 3 Subgroup by dosage schedule: gene therapy versus no gene therapy control,
Outcome 3 All-cause mortality.
Review: Gene therapy for peripheral arterial disease
Comparison: 3 Subgroup by dosage schedule: gene therapy versus no gene therapy control
Outcome: 3 All-cause mortality
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single dosage schedule
Creager 2011 14/213 6/76 12.0 % 0.82 [ 0.30, 2.22 ]
Deev 2017 3/150 2/60 4.1 % 0.59 [ 0.10, 3.63 ]
Makinen 2002 2/35 1/19 1.8 % 1.09 [ 0.09, 12.87 ]
Rajagopalan 2003 0/72 1/33 3.0 % 0.15 [ 0.01, 3.77 ]
Rajagopalan 2007 3/31 2/7 4.3 % 0.27 [ 0.04, 2.03 ]
Subtotal (95% CI) 501 195 25.1 % 0.63 [ 0.31, 1.30 ]
Total events: 22 (Gene therapy), 12 (Control)
Heterogeneity: Chi2 = 1.91, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Repeat dosage schedule
Belch 2011 46/259 39/266 46.0 % 1.26 [ 0.79, 2.00 ]
Deev 2015 5/75 1/25 2.0 % 1.71 [ 0.19, 15.42 ]
Kibbe 2016 1/41 1/11 2.2 % 0.25 [ 0.01, 4.35 ]
Kusumanto 2006 2/27 2/27 2.7 % 1.00 [ 0.13, 7.67 ]
Nikol 2008 6/59 13/66 16.0 % 0.46 [ 0.16, 1.31 ]
Powell 2008 5/80 2/26 4.1 % 0.80 [ 0.15, 4.39 ]
Powell 2010 4/21 1/6 1.8 % 1.18 [ 0.11, 13.07 ]
Subtotal (95% CI) 562 427 74.9 % 1.03 [ 0.70, 1.52 ]
Total events: 69 (Gene therapy), 59 (Control)
Heterogeneity: Chi2 = 4.24, df = 6 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Total (95% CI) 1063 622 100.0 % 0.93 [ 0.66, 1.31 ]
Total events: 91 (Gene therapy), 71 (Control)
Heterogeneity: Chi2 = 7.53, df = 11 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 1.41, df = 1 (P = 0.23), I2 =29%
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Analysis 4.1. Comparison 4 Subgroup by vector type: gene therapy versus no gene therapy control,
Outcome 1 Amputation (above-ankle amputation of the index limb).
Review: Gene therapy for peripheral arterial disease
Comparison: 4 Subgroup by vector type: gene therapy versus no gene therapy control
Outcome: 1 Amputation (above-ankle amputation of the index limb)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Plasmid vector
Belch 2011 67/259 55/266 55.3 % 1.34 [ 0.89, 2.01 ]
Deev 2015 5/75 2/25 3.9 % 0.82 [ 0.15, 4.52 ]
Deev 2017 6/150 2/60 3.8 % 1.21 [ 0.24, 6.16 ]
Kibbe 2016 6/41 1/11 1.9 % 1.71 [ 0.18, 15.95 ]
Kusumanto 2006 3/27 6/27 7.3 % 0.44 [ 0.10, 1.97 ]
Makinen 2002 0/17 0/10 Not estimable
Nikol 2008 8/59 19/66 21.3 % 0.39 [ 0.16, 0.97 ]
Powell 2010 6/21 2/6 3.1 % 0.80 [ 0.11, 5.59 ]
Shigematsu 2010 0/30 0/16 Not estimable
Subtotal (95% CI) 679 487 96.5 % 1.02 [ 0.74, 1.42 ]
Total events: 101 (Gene therapy), 87 (Control)
Heterogeneity: Chi2 = 7.58, df = 6 (P = 0.27); I2 =21%
Test for overall effect: Z = 0.14 (P = 0.88)
2 Viral vector
Makinen 2002 1/18 0/9 0.8 % 1.63 [ 0.06, 44.01 ]
Rajagopalan 2003 1/72 1/33 1.9 % 0.45 [ 0.03, 7.43 ]
Rajagopalan 2007 9/31 0/7 0.8 % 6.33 [ 0.33, 122.40 ]
Subtotal (95% CI) 121 49 3.5 % 2.05 [ 0.43, 9.82 ]
Total events: 11 (Gene therapy), 1 (Control)
Heterogeneity: Chi2 = 1.70, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 800 536 100.0 % 1.06 [ 0.77, 1.46 ]
Total events: 112 (Gene therapy), 88 (Control)
Heterogeneity: Chi2 = 9.41, df = 9 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.72, df = 1 (P = 0.40), I2 =0.0%
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Analysis 4.2. Comparison 4 Subgroup by vector type: gene therapy versus no gene therapy control,
Outcome 2 All-cause mortality.
Review: Gene therapy for peripheral arterial disease
Comparison: 4 Subgroup by vector type: gene therapy versus no gene therapy control
Outcome: 2 All-cause mortality
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Plasmid vector
Belch 2011 46/259 39/266 45.6 % 1.26 [ 0.79, 2.00 ]
Deev 2015 5/75 1/25 2.0 % 1.71 [ 0.19, 15.42 ]
Deev 2017 3/150 2/60 4.0 % 0.59 [ 0.10, 3.63 ]
Kibbe 2016 1/41 1/11 2.2 % 0.25 [ 0.01, 4.35 ]
Kusumanto 2006 2/27 2/27 2.7 % 1.00 [ 0.13, 7.67 ]
Makinen 2002 1/17 1/10 1.7 % 0.56 [ 0.03, 10.12 ]
Nikol 2008 6/59 13/66 15.9 % 0.46 [ 0.16, 1.31 ]
Powell 2008 5/80 2/26 4.1 % 0.80 [ 0.15, 4.39 ]
Powell 2010 4/21 1/6 1.8 % 1.18 [ 0.11, 13.07 ]
Subtotal (95% CI) 729 497 80.0 % 1.00 [ 0.69, 1.45 ]
Total events: 73 (Gene therapy), 62 (Control)
Heterogeneity: Chi2 = 4.74, df = 8 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
2 Viral vector
Creager 2011 14/213 6/76 11.9 % 0.82 [ 0.30, 2.22 ]
Makinen 2002 1/18 0/9 0.9 % 1.63 [ 0.06, 44.01 ]
Rajagopalan 2003 0/72 1/33 2.9 % 0.15 [ 0.01, 3.77 ]
Rajagopalan 2007 3/31 2/7 4.2 % 0.27 [ 0.04, 2.03 ]
Subtotal (95% CI) 334 125 20.0 % 0.64 [ 0.29, 1.43 ]
Total events: 18 (Gene therapy), 9 (Control)
Heterogeneity: Chi2 = 2.04, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 1063 622 100.0 % 0.93 [ 0.66, 1.30 ]
Total events: 91 (Gene therapy), 71 (Control)
Heterogeneity: Chi2 = 7.74, df = 12 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
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Analysis 5.1. Comparison 5 Subgroup by encoding gene: gene therapy versus no gene therapy control,
Outcome 1 Amputation-free survival.
Review: Gene therapy for peripheral arterial disease
Comparison: 5 Subgroup by encoding gene: gene therapy versus no gene therapy control
Outcome: 1 Amputation-free survival









Belch 2011 163/259 180/266 34.9 % 0.81 [ 0.57, 1.16 ]
Nikol 2008 37/59 27/66 28.8 % 2.43 [ 1.18, 4.99 ]
Subtotal (95% CI) 318 332 63.7 % 1.34 [ 0.46, 3.91 ]
Total events: 200 (Gene therapy), 207 (Control)
Heterogeneity: Tau2 = 0.52; Chi2 = 7.12, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.54 (P = 0.59)
2 VEGF encoding
Kusumanto 2006 23/27 16/27 18.8 % 3.95 [ 1.07, 14.65 ]
Subtotal (95% CI) 27 27 18.8 % 3.95 [ 1.07, 14.65 ]
Total events: 23 (Gene therapy), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.040)
3 HGF encoding
Kibbe 2016 30/41 7/11 17.5 % 1.56 [ 0.38, 6.38 ]
Subtotal (95% CI) 41 11 17.5 % 1.56 [ 0.38, 6.38 ]
Total events: 30 (Gene therapy), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 386 370 100.0 % 1.68 [ 0.75, 3.76 ]
Total events: 253 (Gene therapy), 230 (Control)
Heterogeneity: Tau2 = 0.45; Chi2 = 11.29, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 1.68, df = 2 (P = 0.43), I2 =0.0%
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Analysis 5.2. Comparison 5 Subgroup by encoding gene: gene therapy versus no gene therapy control,
Outcome 2 Complete ulcer healing.
Review: Gene therapy for peripheral arterial disease
Comparison: 5 Subgroup by encoding gene: gene therapy versus no gene therapy control
Outcome: 2 Complete ulcer healing
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 FGF encoding
Nikol 2008 10/59 8/66 63.9 % 1.48 [ 0.54, 4.04 ]
Subtotal (95% CI) 59 66 63.9 % 1.48 [ 0.54, 4.04 ]
Total events: 10 (Gene therapy), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.44)
2 HGF encoding
Kibbe 2016 22/40 1/9 7.5 % 9.78 [ 1.12, 85.65 ]
Powell 2010 4/21 0/6 6.1 % 3.34 [ 0.16, 71.10 ]
Shigematsu 2010 4/11 1/5 8.9 % 2.29 [ 0.19, 28.19 ]
Subtotal (95% CI) 72 20 22.5 % 5.06 [ 1.23, 20.84 ]
Total events: 30 (Gene therapy), 2 (Control)
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
3 HIF-1 encoding
Rajagopalan 2007 4/18 1/3 13.6 % 0.57 [ 0.04, 8.05 ]
Subtotal (95% CI) 18 3 13.6 % 0.57 [ 0.04, 8.05 ]
Total events: 4 (Gene therapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 149 89 100.0 % 2.16 [ 1.02, 4.59 ]
Total events: 44 (Gene therapy), 11 (Control)
Heterogeneity: Chi2 = 3.46, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Chi2 = 2.86, df = 2 (P = 0.24), I2 =30%
0.01 0.1 1 10 100
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Analysis 5.3. Comparison 5 Subgroup by encoding gene: gene therapy versus no gene therapy control,
Outcome 3 Amputation (above-ankle amputation of the index limb).
Review: Gene therapy for peripheral arterial disease
Comparison: 5 Subgroup by encoding gene: gene therapy versus no gene therapy control
Outcome: 3 Amputation (above-ankle amputation of the index limb)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 FGF encoding
Belch 2011 67/259 55/266 55.3 % 1.34 [ 0.89, 2.01 ]
Nikol 2008 8/59 19/66 21.3 % 0.39 [ 0.16, 0.97 ]
Subtotal (95% CI) 318 332 76.7 % 1.07 [ 0.75, 1.55 ]
Total events: 75 (Gene therapy), 74 (Control)
Heterogeneity: Chi2 = 5.87, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.39 (P = 0.70)
2 HGF encoding
Kibbe 2016 6/41 1/11 1.9 % 1.71 [ 0.18, 15.95 ]
Powell 2010 6/21 2/6 3.1 % 0.80 [ 0.11, 5.59 ]
Shigematsu 2010 0/30 0/16 Not estimable
Subtotal (95% CI) 92 33 4.9 % 1.14 [ 0.27, 4.81 ]
Total events: 12 (Gene therapy), 3 (Control)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
3 VEGF encoding
Deev 2015 5/75 2/25 3.9 % 0.82 [ 0.15, 4.52 ]
Deev 2017 6/150 2/60 3.8 % 1.21 [ 0.24, 6.16 ]
Kusumanto 2006 3/27 6/27 7.3 % 0.44 [ 0.10, 1.97 ]
Makinen 2002 1/35 0/19 0.8 % 1.70 [ 0.07, 43.66 ]
Rajagopalan 2003 1/72 1/33 1.9 % 0.45 [ 0.03, 7.43 ]
Subtotal (95% CI) 359 164 17.7 % 0.75 [ 0.33, 1.69 ]
Total events: 16 (Gene therapy), 11 (Control)
Heterogeneity: Chi2 = 1.20, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
4 HIF-1 encoding
Rajagopalan 2007 9/31 0/7 0.8 % 6.33 [ 0.33, 122.40 ]
Subtotal (95% CI) 31 7 0.8 % 6.33 [ 0.33, 122.40 ]
Total events: 9 (Gene therapy), 0 (Control)
Heterogeneity: not applicable
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 800 536 100.0 % 1.06 [ 0.77, 1.46 ]
Total events: 112 (Gene therapy), 88 (Control)
Heterogeneity: Chi2 = 9.42, df = 9 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 2.10, df = 3 (P = 0.55), I2 =0.0%
0.01 0.1 1 10 100
Favours Gene therapy Favours Control
Analysis 5.4. Comparison 5 Subgroup by encoding gene: gene therapy versus no gene therapy control,
Outcome 4 All-cause mortality.
Review: Gene therapy for peripheral arterial disease
Comparison: 5 Subgroup by encoding gene: gene therapy versus no gene therapy control
Outcome: 4 All-cause mortality
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 FGF encoding
Belch 2011 46/259 39/266 46.0 % 1.26 [ 0.79, 2.00 ]
Nikol 2008 6/59 13/66 16.0 % 0.46 [ 0.16, 1.31 ]
Subtotal (95% CI) 318 332 62.0 % 1.05 [ 0.69, 1.60 ]
Total events: 52 (Gene therapy), 52 (Control)
Heterogeneity: Chi2 = 2.97, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 0.23 (P = 0.81)
2 HGF encoding
Kibbe 2016 1/41 1/11 2.2 % 0.25 [ 0.01, 4.35 ]
Powell 2008 5/80 2/26 4.1 % 0.80 [ 0.15, 4.39 ]
Powell 2010 4/21 1/6 1.8 % 1.18 [ 0.11, 13.07 ]
Subtotal (95% CI) 142 43 8.2 % 0.73 [ 0.22, 2.50 ]
Total events: 10 (Gene therapy), 4 (Control)
Heterogeneity: Chi2 = 0.70, df = 2 (P = 0.70); I2 =0.0%
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Gene therapy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.49 (P = 0.62)
3 VEGF encoding
Deev 2015 5/75 1/25 2.0 % 1.71 [ 0.19, 15.42 ]
Deev 2017 3/150 2/60 4.1 % 0.59 [ 0.10, 3.63 ]
Kusumanto 2006 2/27 2/27 2.7 % 1.00 [ 0.13, 7.67 ]
Makinen 2002 2/35 1/19 1.8 % 1.09 [ 0.09, 12.87 ]
Rajagopalan 2003 0/72 1/33 3.0 % 0.15 [ 0.01, 3.77 ]
Subtotal (95% CI) 359 164 13.5 % 0.81 [ 0.32, 2.09 ]
Total events: 12 (Gene therapy), 7 (Control)
Heterogeneity: Chi2 = 1.71, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
4 HIF-1 encoding
Creager 2011 14/213 6/76 12.0 % 0.82 [ 0.30, 2.22 ]
Rajagopalan 2007 3/31 2/7 4.3 % 0.27 [ 0.04, 2.03 ]
Subtotal (95% CI) 244 83 16.3 % 0.68 [ 0.28, 1.63 ]
Total events: 17 (Gene therapy), 8 (Control)
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 1063 622 100.0 % 0.93 [ 0.66, 1.31 ]
Total events: 91 (Gene therapy), 71 (Control)
Heterogeneity: Chi2 = 7.53, df = 11 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 1.06, df = 3 (P = 0.79), I2 =0.0%
0.01 0.1 1 10 100
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A P P E N D I C E S
Appendix 1. Search strategies
Source Search strategy Hits retrieved
CENTRAL #1 MESH DESCRIPTOR Arteriosclerosis 872
#2 MESH DESCRIPTOR Arteriolosclerosis EX-
PLODE ALL TREES 0
#3 MESH DESCRIPTOR Arteriosclerosis Obliter-
ans 73
#4 MESH DESCRIPTOR Atherosclerosis 684
#5 MESH DESCRIPTOR Arterial Occlusive Dis-
eases 746
#6 MESH DESCRIPTOR Intermittent Claudica-
tion 738
#7 MESH DESCRIPTOR Ischemia 823
#8 MESH DESCRIPTOR Peripheral Vascular Dis-
eases EXPLODE ALL TREES 2288
#9 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD ):TI,AB,KY 10322
#10 (((arter* or vascular or vein* or veno* or pe-
ripher*) near3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*))):TI,AB,KY 9288
#11 (peripheral near3 dis*):TI,AB,KY 3862
#12 (claudic* or IC):TI,AB,KY 3571
#13 arteriopathic:TI,AB,KY 7
#14 dysvascular*:TI,AB,KY 12
#15 ((leg near3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*))):TI,AB,KY 110
#16 ((limb near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*))):TI,AB,KY 185
#17 (((lower near3 extrem*) near3 (occlus* or re-
occlus* or re-occlus* or steno* or restenos* or ob-
struct* or lesio* or block* or harden* or stiffen* or
obliter*))):TI,AB,KY 91
#18 MESH DESCRIPTOR Iliac Artery EX-
PLODE ALL TREES 154
#19 MESH DESCRIPTOR Popliteal Artery EX-
PLODE ALL TREES 294
#20 MESH DESCRIPTOR Femoral Artery EX-
PLODE ALL TREES 873
#21 MESH DESCRIPTOR Tibial Arteries EX-
PLODE ALL TREES 35
#22 ((((femor* or iliac or popliteal or fempop*
or crural or poplite* or infrapopliteal or inguinal
1263
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(Continued)
or femdist* or inguinal or infrainquinal or tibial)
near3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*) ))):TI,AB,KY 1362
#23 (isch* or CLI):TI,AB,KY 27272
#24 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR
#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #
13 OR #14 OR #15 OR #16 OR #17 OR #18 OR
#19 OR #20 OR #21 OR #22 OR #23 49656
#25 MESH DESCRIPTOR Genetic Therapy EX-
PLODE ALL TREES 148
#26 MESH DESCRIPTOR Gene Transfer Tech-
niques EXPLODE ALL TREES 120
#27 MESH DESCRIPTOR Genes EXPLODE
ALL TREES 1544
#28 MESH DESCRIPTOR Angiogenesis Inducing
Agents EXPLODE ALL TREES 44
#29 MESH DESCRIPTOR DNA Viruses EX-
PLODE ALL TREES 2359
#30 MESH DESCRIPTOR RNA Viruses EX-
PLODE ALL TREES 6023
#31 angiogen* :TI,AB,KY 2935
#32 arteriogen* :TI,AB,KY 37
#33 vasculogen*:TI,AB,KY 137
#34 adenovirus:TI,AB,KY 455
#35 ((gene* near3 (therap* or treat* or transfer) )):
TI,AB,KY 7837
#36 transgene*:TI,AB,KY 102
#37 MESH DESCRIPTOR Angiogenic Proteins
EXPLODE ALL TREES 1032
#38 MESH DESCRIPTOR Fibroblast Growth Fac-
tors EXPLODE ALL TREES 304
#39 MESH DESCRIPTOR Endothelial Growth
Factors EXPLODE ALL TREES 64
#40 MESH DESCRIPTOR Genetic Vectors EX-
PLODE ALL TREES 152
#41 MESH DESCRIPTOR Vascular Endothelial
Growth Factors EXPLODE ALL TREES 968
#42 del-1:TI,AB,KY 7
#43 VLTS:TI,AB,KY 3
#44 VEGF :TI,AB,KY 2229
#45 FGF:TI,AB,KY 315
#46 ((growth near3 factor)):TI,AB,KY 11682
#47 HGF*:TI,AB,KY 213
#48 HIF*:TI,AB,KY 337
#49 25# OR #26 OR #27 OR #28 OR #29 OR #
30 OR #31 OR #32 OR #33 OR #34 OR #35 OR
#36 OR #37 OR #38 OR #39 OR #40 OR #41
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OR #42 OR #43 OR #44 OR #45 OR #46 OR #
47 OR #48 30516
#50 #24 AND #49 1365
#51 * NOT SR-PVD:CC 1088498
#52 #51 AND #50 1263
Clinicaltrials.gov (peripheral OR arterial OR claudication OR is-
chemia OR ischaemia) AND (gene OR plasmid OR
DNA)
21
ICTRP Search Portal (peripheral OR arterial OR claudication OR is-
chemia OR ischaemia) AND (gene OR plasmid OR
DNA)
166
MEDLINE (2017 only) 1 *Arteriosclerosis/ 39872
2 exp Arteriolosclerosis/ 159
3 Arteriosclerosis Obliterans/ 4192
4 Atherosclerosis/ 32486
5 Arterial Occlusive Diseases/ 28247
6 Intermittent Claudication/ 8184
7 Ischemia/ 50319
8 exp Peripheral Vascular Diseases/ 53026
9 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD).ti,ab. 179650
10 ((arter* or vascular or vein* or veno* or peripher*)
adj3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*)).ti,ab. 151160
11 (peripheral adj3 dis*).ti,ab. 39826
12 (claudic* or IC).ti,ab. 64504
13 (isch* or CLI).ti,ab. 364490
14 arteriopathic.ti,ab. 181
15 dysvascular*.ti,ab. 222
16 (leg adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 745
17 (limb adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 1860
18 (lower adj3 extrem* adj3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*)).
ti,ab. 1539
19 Popliteal Artery/ 9465
20 Iliac Artery/ 14224
21 Femoral Artery/ 28635
22 Tibial Arteries/ 1574
23 ((femor* or iliac or popliteal or fempop* or crural
or poplite* or infrapopliteal or inguinal or femdist*
359
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or inguinal or infrainquinal or tibial) adj3 (occlus*
or reocclus* or re-occlus* or steno* or restenos* or
obstruct* or lesio* or block* or harden* or stiffen*
or obliter*)).ti,ab. 10135
24 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22 or 23 815284
25 Genetic Therapy/ 48081
26 Gene Transfer Techniques/ 27752
27 Genes/ 60254
28 Angiogenesis Inducing Agents/ 3560
29 DNA Viruses/ 4246





35 (gene* adj3 (therap* or treat* or transfer)).ti,ab.
138947
36 transgene*.ti,ab. 40856
37 Angiogenic Proteins/ 1373
38 Fibroblast Growth Factors/ 12333
39 Endothelial Growth Factors/ 8320
40 Genetic Vectors/ 77090









50 24 and 49 32344
51 randomized controlled trial.pt. 505458
52 controlled clinical trial.pt. 100426
53 randomized.ab. 442267
54 placebo.ab. 205474





60 exp animals/ not humans.sh. 4743200
61 59 not 60 3847673
62 50 and 61 5415
63 2017*.ed. 953719
64 62 and 63 359
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Embase (2017 only) 1 *Arteriosclerosis/ 8109
2 exp Arteriolosclerosis/ 453
3 Arteriosclerosis Obliterans/ 11088
4 Atherosclerosis/ 111646
5 Arterial Occlusive Diseases/ 5724
6 Intermittent Claudication/ 5963
7 Ischemia/ 58363
8 exp Peripheral Vascular Diseases/ 1248235
9 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD).ti,ab. 187583
10 ((arter* or vascular or vein* or veno* or peripher*)
adj3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*)).ti,ab. 140324
11 (peripheral adj3 dis*).ti,ab. 41933
12 (claudic* or IC).ti,ab. 50908
13 (isch* or CLI).ti,ab. 387776
14 arteriopathic.ti,ab. 81
15 dysvascular*.ti,ab. 168
16 (leg adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 671
17 (limb adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 2084
18 (lower adj3 extrem* adj3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*)).
ti,ab. 1417
19 Popliteal Artery/ 5109
20 Iliac Artery/ 9640
21 Femoral Artery/ 20298
22 Tibial Arteries/ 2033
23 ((femor* or iliac or popliteal or fempop* or crural
or poplite* or infrapopliteal or inguinal or femdist*
or inguinal or infrainquinal or tibial) adj3 (occlus*
or reocclus* or re-occlus* or steno* or restenos* or
obstruct* or lesio* or block* or harden* or stiffen*
or obliter*)).ti,ab. 10508
24 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22 or 23 1513904
25 Genetic Therapy/ 48294
26 Gene Transfer Techniques/ 35347
27 Genes/ 420137
28 Angiogenesis Inducing Agents/ 8523
29 DNA Viruses/ 3506
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35 (gene* adj3 (therap* or treat* or transfer)).ti,ab.
153680
36 transgene*.ti,ab. 43588
37 Angiogenic Proteins/ 721
38 Fibroblast Growth Factors/ 12569
39 Endothelial Growth Factors/ 1862
40 Genetic Vectors/ 15497









50 24 and 49 79823
51 randomized controlled trial/ 435001
52 controlled clinical trial/ 407751
53 random$.ti,ab. 1126865
54 randomization/ 68057
55 intermethod comparison/ 222998
56 placebo.ti,ab. 214175
57 (compare or compared or comparison).ti.
325422
58 ((evaluated or evaluate or evaluating or assessed
or assess) and (compare or compared or comparing
or comparison)).ab. 1554249
59 (open adj label).ti,ab. 59761
60 ((double or single or doubly or singly) adj (blind
or blinded or blindly)).ti,ab. 152758
61 double blind procedure/ 118736
62 parallel group$1.ti,ab. 18876
63 (crossover or cross over).ti,ab. 69846
64 ((assign$ or match or matched or allocation)
adj5 (alternate or group$1 or intervention$1 or
patient$1 or subject$1 or participant$1)).ti,ab.
240046
65 (assigned or allocated).ti,ab. 281154
66 (controlled adj7 (study or design or trial)).ti,ab.
251707
67 (volunteer or volunteers).ti,ab. 167509
68 trial.ti. 205045
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69 or/51-68 3358247
70 50 and 69 15845
71 2017*.dc. 1625525
72 70 and 71 1280
CINAHL (2017 only) S55 S53 AND S54 53
S54 EM 2017 177,369
S53 S45 AND S52 821
S52 S46 OR S47 OR S48 OR S49 OR S50 OR S51
951,352
S51 TX randomly 41,710
S50 TX “treatment as usual” 708
S49 TX “double-blind*” 755,009
S48 TX “single-blind*” 8,666
S47 TX trial 236,475
S46 MH “Clinical Trials” 90,793
S45 S24 AND S44 3,117
S44 S25 OR S26 OR S27 OR S28 OR S29 OR S30
OR S31 OR S32 OR S33 OR S34 OR S35 OR S36
OR S37 OR S38 OR S39 OR S40 OR S41 OR S42
OR S43 51,639
S43 TX HIF* 794
S42 TX HGF* 268
S41 TX (growth N3 factor) 16,219
S40 TX FGF 578
S39 TX VEGF 2,696
S38 TX VLTS 58
S37 TX del-1 445
S36 (MH “Vascular Endothelial Growth Factors+”)
1235
S35 (MH “Endothelial Growth Factors”) 1,003
S34 (MH “Angiogenic Proteins+”) 1259
S33 TX transgene* 534
S32 TX (gene* N3 (therap* or treat* or transfer) )
12,465
S31 TX adenovirus 927
S30 TX vasculogen* 148
S29 TX arteriogen* 70
S28 TX angiogen* 5,607
S27 (MH “RNA Viruses+”) 4,533
S26 (MH “DNA Viruses+”) 67
S25 (MH “Genes”) 14,893
S24 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
OR S14 OR S15 OR S16 OR S17 OR S18 OR S19
OR S20 OR S21 OR S22 OR S23 87,781
S23 TX (((femor* or iliac or popliteal or fempop*
or crural or poplite* or infrapopliteal or inguinal
or femdist* or inguinal or infrainquinal or tibial)
53
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N3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*) )) 1,035
S22 (MH “Tibial Arteries”) 134
S21 (MH “Femoral Artery”) 1,180
S20 (MH “Popliteal Artery”) 352
S19 (MH “Iliac Artery”) 449
S18 ((lower N3 extrem*) N3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*))
112
S17 (limb N3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)) 236
S16 TX (leg N3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)) 121
S15 TX dysvascular* 165
S14 TX arteriopathic 10
S13 TX (isch* or CLI) 37,892
S12 TX (claudic* or IC) 6,848
S11 (peripheral N3 dis*) 8,536
S10 TX (arter* or vascular or vein* or veno* or pe-
ripher*) N3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)) 12,207
S9 TX (arter* or vascular or vein* or veno* or pe-
ripher*) near3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*) ) 0
S8 TX (atherosclero* or arteriosclero* or PVD or
PAOD or PAD ) 25,447
S7 (MH “Peripheral Vascular Diseases+”) 9,616
S6 (MH “Ischemia”) 3,239
S5 (MH “Intermittent Claudication”) 831
S4 (MH “Arterial Occlusive Diseases”) 1,581
S3 (MH “Atherosclerosis”) 3,138
S2 (MH “Atherosclerosis”) 3,138
S1 (MH “Arteriosclerosis”) 4,830
AMED (2017 only) 1 Atherosclerosis/ 209
2 Intermittent Claudication/ 72
3 Ischemia/ 253
4 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD).ti,ab. 783
5 ((arter* or vascular or vein* or veno* or peripher*)
adj3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*)).ti,ab. 451
3
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6 (peripheral adj3 dis*).ti,ab. 431
7 (claudic* or IC).ti,ab. 1020
8 (isch* or CLI).ti,ab. 1615
9 arteriopathic.ti,ab. 1
10 dysvascular*.ti,ab. 56
11 (leg adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 21
12 (limb adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 31
13 (lower adj3 extrem* adj3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*)).
ti,ab. 25
14 ((femor* or iliac or popliteal or fempop* or crural
or poplite* or infrapopliteal or inguinal or femdist*
or inguinal or infrainquinal or tibial) adj3 (occlus*
or reocclus* or re-occlus* or steno* or restenos* or

















29 27 and 28 88
30 2017*.up. 6951
31 29 and 30 4
TOTAL before de-duplication 3597
TOTAL after de-duplication 3223
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JS: protocol drafting, review drafting, and future review updates.
GS: protocol drafting, review drafting, and future review updates.
D E C L A R A T I O N S O F I N T E R E S T
RF: none known.
AL: has received travel, accommodation, and meeting expenses from Pfizer, Bristol-Myers Squibb, and Novartis; travel expenses from
Novo Nordisk, Lilly, and Sanofi; and educational funding from Novartis for completion of a Post Graduate Diploma in Clinical
Education. AL is a member of the Scientific Advisory Board for pharmacological treatment of diabetes mellitus and dyslipidaemia
(Novo Nordisk, AstraZeneca, Sanofi, Lilly, Janssen, and Amgen). AL has received payment from Novo Nordisk and Lilly for lectures
related to diabetes mellitus. AL is an author on the patent “Osteopontin for the prediction and treatment of cardiovascular diseases”
(US Patent Number: US8323968B2). This invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for
treatment of cardiovascular disease or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the
risk of development of these cardiovascular complications. In particular, the invention provides compositions and methods based on
osteopontin and the genes encoding osteopontin. However, this patent is not directly related to the use of osteopontin or any other
aspect of this review. In our Cochrane review, we focus specifically on genetic modification of muscle and surrounding tissues (by direct
intramuscular or intra-arterial injections) of the lower limbs of patients with peripheral arterial disease. Whilst both the patent and the
Cochrane Review involved gene transfer, they are two completely distinct entities.
VB: none known.
JS: has received travel support from Novo Nordisk to attend American Diabetes Association meetings and has received grant funding
from Dompe for participation in an RCT of reparixin vs placebo in pancreatic islet transplant recipients.
GS: none known.
S O U R C E S O F S U P P O R T
Internal sources
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External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Office.
• National Institute for Health Research (NIHR), UK.
This project was supported by the NIHR, via Cochrane Incentive Scheme Award funding to Cochrane Vascular (17/62/09). The
views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, the National Health Service, or the Department of Health.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Several of the outcomes from the protocol were written as “improvement in...”, which indicates that we are looking only for improvements
and would not report a worsening of the outcome if we found this information. We have amended this and removed “improvement”.
For the outcome “Ulcer healing”, we removed the description “as measured by surface area of ulceration in cm²”, as none of the
included studies reported ulcer healing in this manner. However, several of the included studies reported the number of ulcers that
healed completely, which we deemed as sufficiently objective; we chose to include these studies in the meta-analysis.
For clarification of our methods, we changed the way we dealt with studies involving direct growth factor treatment or cell therapy
from “excluded” to “not relevant”; therefore we have not included them in the list of excluded studies.
N O T E S
Parts of the Methods section of the protocol for this review are based on a standard template established by Cochrane Vascular.
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